Methods and compositions for delivering mrna coded antibodies

ABSTRACT

The present invention provides, among other things, methods and compositions for delivering an antibody in vivo by administering to a subject in need thereof one or more mRNAs encoding a heavy chain and a light chain of an antibody, and wherein the antibody is expressed systemically in the subject. In some embodiments, the one or more mRNAs comprise a first mRNA encoding the heavy chain and a second mRNA encoding the light chain of the antibody.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. application Ser.No. 16/129,412 filed on Sep. 12, 2018, now allowed, which is acontinuation application of U.S. application Ser. No. 14/775,835 filedon Sep. 14, 2015, issued as U.S. Pat. No. 10,087,247 on Oct. 2, 2018,which is the National Stage Entry of PCT/US14/27717 filed on Mar. 14,2014, which claims priority to U.S. provisional patent application Ser.Nos. 61/784,903, filed on Mar. 14, 2013, and 61/920,165, filed on Dec.23, 2013, the contents of which are hereby incorporated by reference intheir entirety.

BACKGROUND

Antibodies are known to have powerful therapeutic effects and arecurrently used for the treatment of a range of diseases includingcancer, autoimmune diseases, cardiovascular disease, and transplantrejection. Traditionally, therapeutic antibodies are produced byrecombinant technology, formulated and then administered to patients inneed of antibody therapy. However, antibody production and formulationis highly expensive. In addition, many antibodies only have a very shorthalf-life in vivo and therefore, may not reach their target antigen ortarget tissue before being degraded. To achieve desired efficacy,antibody therapy often requires high doses and frequent administration.

Gene therapy and genetic vaccination, also known as DNA vaccination,provide alternative approaches for delivery of large amounts ofantibodies in vivo. However, the use of DNA as an agent in gene therapyand genetic vaccination may cause some safety concerns. For example, DNAis degraded slowly in the bloodstream. Formation of anti-DNA antibodiesmay occur (Gilkeson et al., J. Clin. Invest. 1995, 95: 1398-1402). Thepossible persistence of (foreign) DNA in the organism can thus lead to ahyperactivation of the immune system, which was known to result insplenomegaly in mice (Montheith et al., Anticancer Drug Res. 1997,12(5): 421-432). Furthermore, DNA integration can cause mutations in thehost genome by interrupting an intact gene.

SUMMARY OF THE INVENTION

The present invention provides an improved method for safer and moreeffective delivery of antibodies in vivo based on messenger RNA (mRNA)delivery technology. The present invention is, in part, based on thesurprising discovery that production of fully assembled multi-chainantibodies can be accomplished in vivo by delivering exogenous mRNAsencoding a heavy chain and a light chain of the antibody, even when theheavy chain and light chain are delivered by separate mRNAs. Asillustrated by non-limiting examples described in the Examples sectionbelow, when heavy chain and light chain encoding mRNA constructs,encapsulated in liposomes, were injected intravenously into mice,significant amounts of desired mRNA encoded antibody can be detected inmouse serum within six hours post-injection with a peak after 72 or 96hours. The systemic expression of the antibody persisted even afterthree weeks post-injection. Thus, the present inventors havesuccessfully demonstrated that multi-chain therapeutic antibodies can bedelivered by mRNAs and produced by the patient's body itself, whichmakes it possible to eliminate the highly expensive recombinant antibodymanufacturing process. In addition, contrary to the transient andvulnerable nature of mRNAs, the antibodies produced from the mRNAs aresurprisingly long lasting and can achieve systemic distributionefficiently. The transient nature of mRNAs can also minimize the safetyconcern typically associated with foreign nucleic acids. Thus, thepresent invention provides a safer, cheaper and more effective antibodydelivery approach for therapeutic uses.

In one aspect, the present invention provides a method of delivering anantibody in vivo, by administering to a subject in need thereof one ormore mRNAs encoding a heavy chain and a light chain of an antibody, andwherein the antibody is expressed systemically in the subject. In someembodiments, the one or more mRNAs comprise a first mRNA encoding theheavy chain and a second mRNA encoding the light chain of the antibody.In some embodiments, the one or more mRNAs comprise a single mRNAencoding both the heavy chain and the light chain of the antibody.

In some embodiments, a heavy chain or light chain encoding mRNAcomprises a sequence encoding a signal peptide. In some embodiments, aheavy chain or light chain encoding mRNA comprises a sequence encoding ahuman growth hormone (hGH) signal peptide (e.g, SEQ ID NO: 9 or SEQ IDNO: 10). In some embodiments, the sequence encoding a signal peptidesequence (e.g., SEQ ID NO:9 or SEQ ID NO:10) is linked, directly orindirectly, to the heavy chain or light chain encoding mRNA sequence atthe N-terminus.

In some embodiments, the first mRNA encoding the heavy chain and thesecond mRNA encoding the light chain are present at a ratio rangingbetween approximately 10:1 to 1:10 (e.g., between approximately 9:1 to1:9, 8:1 to 1:8, 7:1 to 1:7, 6:1 to 1:6, 5:1 to 1:5, 4:1 to 1:4, 3:1 to1:3, or 2:1 to 1:2). In some embodiments, the first mRNA encoding theheavy chain and the second mRNA encoding the light chain are present ata ratio ranging between approximately 4:1 to 1:4. In some embodiments,the first mRNA encoding the heavy chain and the second mRNA encoding thelight chain are present at a ratio of approximately 10:1, 9:1, 8:1, 7:1,6:1, 5:1, 4:1, 3:1, 2:1 or 1:1. In some embodiments, the first mRNAencoding the heavy chain and the second mRNA encoding the light chainare present at a ratio of approximately 4:1. In some embodiments, thefirst mRNA encoding the heavy chain and the second mRNA encoding thelight chain are present at a ratio of approximately 1:1. In someembodiments, the first mRNA encoding the heavy chain and the second mRNAencoding the light chain are present at a ratio greater than 1 (e.g.,ranging between approximately 10:1 to 1:1, 9:1 to 1:1, 8:1 to 1:1, 7:1to 1:1, 6:1 to 1:1, 5:1 to 1:1, 4:1 to 1:1, 3:1 to 1:1, or 2:1 to 1:1).

In some embodiments, the one or more mRNAs encoding the heavy chain andthe light chain of the antibody are delivered via a polymer and/or lipidbased delivery vehicle. In some embodiments, the one or more mRNAsencoding the heavy chain and the light chain of the antibody areencapsulated within one or more liposomes. In some embodiments, thefirst mRNA encoding the heavy chain and the second mRNA encoding thelight chain are encapsulated in separate liposomes. In some embodiments,the first mRNA encoding the heavy chain and the second mRNA encoding thelight chain are encapsulated in the same liposome. In some embodiments,the one or more liposomes comprise one or more of cationic lipid,neutral lipid, cholesterol-based lipid, and PEG-modified lipid. In someembodiments, the one or more liposomes comprise cationic lipid, neutrallipid, cholesterol-based lipid, and PEG-modified lipid.

In some embodiments, the one or more liposomes have a size no greaterthan about 250 nm (e.g., no greater than about 225 nm, 200 nm, 175 nm,150 nm, 125 nm, 100 nm, 75 nm, or 50 nm). In some embodiments, the oneor more liposomes have a size no greater than about 150 nm. In someembodiments, the one or more liposomes have a size no greater than about100 nm. In some embodiments, the one or more liposomes have a size nogreater than about 75 nm. In some embodiments, the one or more liposomeshave a size no greater than about 50 nm.

In some embodiments, the one or more liposomes have a size ranging fromabout 250-10 nm (e.g., ranging from about 225-10 nm, 200-10 nm, 175-10nm, 150-10 nm, 125-10 nm, 100-10 nm, 75-10 nm, or 50-10 nm). In someembodiments, the one or more liposomes have a size ranging from about250-100 nm (e.g., ranging from about 225-100 nm, 200-100 nm, 175-100 nm,150-100 nm). In some embodiments, the one or more liposomes have a sizeranging from about 100-10 nm (e.g., ranging from about 90-10 nm, 80-10nm, 70-10 nm, 60-10 nm, or 50-10 nm).

In some embodiments, the one or more mRNAs are modified to enhancestability. In some embodiments, the one or more mRNAs are modified toinclude a modified nucleotide, a modified sugar backbone, a capstructure, a poly A tail, a 5′ and/or 3′ untranslated region. In someembodiments, the one or more mRNAs are unmodified.

In some embodiments, the one or more mRNAs are administeredintravenously. In some embodiments, the one or more mRNAs areadministered intraperitoneally. In some embodiments, the one or moremRNAs are administered subcutaneously. In some embodiments, the one ormore mRNAs are administered via pulmonary administration.

In some embodiments, the systemic expression of the antibody isdetectable at least about 6 hours, 12 hours, 24 hours, 36 hours, 48hours, 60 hours, 72 hours, 96 hours, 120 hours, 144 hours, 156 hours,168 hours, or 180 hours post-administration (e.g., post singleadministration). In some embodiments, the systemic expression of theantibody is detectable at least about 1 day, 2 days, 3 days, 4 days, 5days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13days, 14 days, 15 days, 20 days, 22 days, 25 days, or 30 dayspost-administration (e.g., post single administration). In someembodiments, the systemic expression of the antibody is detectable atleast about 0.5 weeks, 1 week, 1.5 weeks, 2 weeks, 2.5 weeks, 3 weeks,3.5 weeks, 4 weeks, 4.5 weeks, 5 weeks, 5.5 weeks, 6 weeks, 6.5 weeks, 7weeks, 7.5 weeks, or 8 weeks post-administration (e.g., post singleadministration). In some embodiments, the systemic expression of theantibody is detectable at least about 1 month, 2 months, 3 months, or 4months post-administration (e.g., post single administration).

In some embodiments, the antibody is an intact immunoglobulin, (Fab)₂,(Fab′)₂, Fab, Fab′ or scFv. In some embodiments, the antibody is an IgG.In some embodiments, the antibody is selected from the group consistingof anti-CCL2, anti-lysyl oxidase-like-2 (LOXL2), anti-Flt-1, anti-TNF-α,anti-Interleukin-2Rα receptor (CD25), anti-TGF_(β), anti-B-cellactivating factor, anti-alpha-4 integrin, anti-BAGE, anti-β-catenin/m,anti-Bcr-abl, anti-C5, anti-CA125, anti-CAMEL, anti-CAP-1, anti-CASP-8,anti-CD4, anti-CD19, anti-CD20, anti-CD22, anti-CD25, anti-CDC27/m,anti-CD 30, anti-CD33, anti-CD52, anti-CD56, anti-CD80, anti-CDK4/m,anti-CEA, anti-CT, anti-CTL4, anti-Cyp-B, anti-DAM, anti-EGFR,anti-ErbB3, anti-ELF2M, anti-EMMPRIN, anti-EpCam, anti-ETV6-AML1,anti-HER2, anti-G250, anti-GAGE, anti-GnT-V, anti-Gp100, anti-HAGE,anti-HER-2/neu, anti-HLA-A*0201-R170I, anti-IGF-1R, anti-IL-2R,anti-IL-5, anti-MC1R, anti-myosin/m, anti-MUC1, anti-MUM-1, -2, -3,anti-proteinase-3, anti-p190 minor bcr-abl, anti-Pml/RARα, anti-PRAMS,anti-PSA, anti-PSM, anti-PSMA, anti-RAGE, anti-RANKL, anti-RU1 or RU2,anti-SAGE, anti-SART-1 or anti-SART-3, anti-survivin, anti-TEL/AML1,anti-TPI/m, anti-TRP-1, anti-TRP-2, anti-TRP-2/INT2, and anti-VEGF oranti-VEGF receptor.

In another aspect, the present invention provides a method of producingan antibody by administering to a cell a first mRNA encoding a heavychain and a second mRNA encoding a light chain of an antibody, andwherein the antibody is produced by the cell. In some embodiments, thecell is a mammalian cell. In some embodiments, the cell is a human cell.In some embodiments, the cell is a cultured cell. In some embodiments,the cell is a cell within a living organism. In some embodiments, theantibody is expressed intracellularly. In some embodiments, the antibodyis secreted by the cell.

In yet another aspect, the present invention provides compositionsincluding a first mRNA encoding a heavy chain and a second mRNA encodinga light chain of an antibody, wherein the first mRNA and the second mRNAare encapsulated in one or more liposomes.

Among other things, the present invention also provides exemplary mRNAsencoding a heavy chain and a light chain of specific antibodies such as,for example, an anti-CCL2 antibody, and compositions containing thesame. In certain embodiments, the present invention provides an mRNAencoding a heavy chain of an anti-CCL2 antibody having a sequence atleast 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%,or 99% identical to SEQ ID NO:1 or SEQ ID NO:2, as described herein. Incertain specific embodiments, the present invention provides an mRNAencoding a heavy chain of an anti-CCL2 antibody having a sequence of SEQID NO:1 or SEQ ID NO:2, as described herein. In certain embodiments, thepresent invention provides an mRNA encoding a light chain of ananti-CCL2 antibody having a sequence at least 50%, 55%, 60%, 65%, 70%,75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:3or SEQ ID NO:4, as described herein. In certain specific embodiments,the present invention provides an mRNA encoding a light chain of ananti-CCL2 antibody having a sequence of SEQ ID NO:3 or SEQ ID NO:4, asdescribed herein.

As used in this application, the terms “about” and “approximately” areused as equivalents. Any numerals used in this application with orwithout about/approximately are meant to cover any normal fluctuationsappreciated by one of ordinary skill in the relevant art.

Other features, objects, and advantages of the present invention areapparent in the detailed description that follows. It should beunderstood, however, that the detailed description, while indicatingembodiments of the present invention, is given by way of illustrationonly, not limitation. Various changes and modifications within the scopeof the invention will become apparent to those skilled in the art fromthe detailed description.

BRIEF DESCRIPTION OF THE DRAWING

The following figures are for illustration purposes only and not forlimitation.

FIG. 1 shows an exemplary bar graph of IgG protein levels, as determinedby ELISA, observed after treating HCL1 cells with mRNA using providedmethods.

FIG. 2 shows an exemplary bar graph of IgG protein levels, as determinedby ELISA, observed after treating cells with mRNA using providedmethods.

FIG. 3 depicts the results of a western blot examining protein levelsresulting from introduction of mRNA, according to provided methods, inHCL1 cells after 24 and 48 hours.

FIG. 4 shows an exemplary bar graph of CCL2 antibody levels asdetermined via ELISA in the serum of mice exposed to mRNA according toprovided methods for 6, 24, 48, or 72 hours.

FIG. 5 shows an exemplary bar graph of α-VEGF antibody levels asdetermined via ELISA in the serum of mice after single dose of α-VEGFmRNA.

FIG. 6 shows an exemplary bar graph of α-VEGF antibody levels asdetermined via ELISA in the serum of individually identified mice aftersingle dose of α-VEGF mRNA.

FIG. 7 shows an exemplary bar graph of in vivo production of ananti-human VEGF antibody in wild type mice 24 hours after dosing withα-VEGF mRNA loaded cKK-E12 lipid nanoparticles (LNP). Mice were dosedvia either tail vein injection or subcutaneous (SC) injection.

DEFINITIONS

In order for the present invention to be more readily understood,certain terms are first defined below. Additional definitions for thefollowing terms and other terms are set forth throughout thespecification.

Amino acid: As used herein, term “amino acid,” in its broadest sense,refers to any compound and/or substance that can be incorporated into apolypeptide chain. In some embodiments, an amino acid has the generalstructure H₂N—C(H)(R)—COOH. In some embodiments, an amino acid is anaturally occurring amino acid. In some embodiments, an amino acid is asynthetic amino acid; in some embodiments, an amino acid is a d-aminoacid; in some embodiments, an amino acid is an I-amino acid. “Standardamino acid” refers to any of the twenty standard I-amino acids commonlyfound in naturally occurring peptides. “Nonstandard amino acid” refersto any amino acid, other than the standard amino acids, regardless ofwhether it is prepared synthetically or obtained from a natural source.As used herein, “synthetic amino acid” encompasses chemically modifiedamino acids, including but not limited to salts, amino acid derivatives(such as amides), and/or substitutions. Amino acids, including carboxy-and/or amino-terminal amino acids in peptides, can be modified bymethylation, amidation, acetylation, protecting groups, and/orsubstitution with other chemical groups that can change the peptide'scirculating half-life without adversely affecting their activity. Aminoacids may participate in a disulfide bond. Amino acids may comprise oneor posttranslational modifications, such as association with one or morechemical entities (e.g., methyl groups, acetate groups, acetyl groups,phosphate groups, formyl moieties, isoprenoid groups, sulfate groups,polyethylene glycol moieties, lipid moieties, carbohydrate moieties,biotin moieties, etc.). The term “amino acid” is used interchangeablywith “amino acid residue,” and may refer to a free amino acid and/or toan amino acid residue of a peptide. It will be apparent from the contextin which the term is used whether it refers to a free amino acid or aresidue of a peptide.

Animal: As used herein, the term “animal” refers to any member of theanimal kingdom. In some embodiments, “animal” refers to humans, at anystage of development. In some embodiments, “animal” refers to non-humananimals, at any stage of development. In certain embodiments, thenon-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit,a monkey, a dog, a cat, a sheep, cattle, a primate, and/or a pig). Insome embodiments, animals include, but are not limited to, mammals,birds, reptiles, amphibians, fish, insects, and/or worms. In someembodiments, an animal may be a transgenic animal,genetically-engineered animal, and/or a clone.

Antibody: As used herein, the term “antibody” encompasses both intactantibody and antibody fragment. Typically, an intact “antibody” is animmunoglobulin that binds specifically to a particular antigen. Anantibody may be a member of any immunoglobulin class, including any ofthe human classes: IgG, IgM, IgA, IgE, and IgD. A typical immunoglobulin(antibody) structural unit as understood in the art, is known tocomprise a tetramer. Each tetramer is composed of two identical pairs ofpolypeptide chains, each pair having one “light” (approximately 25 kD)and one “heavy” chain (approximately 50-70 kD). The N-terminus of eachchain defines a variable region of about 100 to 110 or more amino acidsprimarily responsible for antigen recognition. The terms “variable lightchain” (VL) and “variable heavy chain” (VH) refer to these light andheavy chains respectively. Each variable region is further subdividedinto hypervariable (HV) and framework (FR) regions. The hypervariableregions comprise three areas of hypervariability sequence calledcomplementarity determining regions (CDR 1, CDR 2 and CDR 3), separatedby four framework regions (FR1, FR2, FR2, and FR4) which form abeta-sheet structure and serve as a scaffold to hold the HV regions inposition. The C-terminus of each heavy and light chain defines aconstant region consisting of one domain for the light chain (CL) andthree for the heavy chain (CH1, CH2 and CH3). In some embodiments, theterms “intact antibody” or “fully assembled antibody” are used inreference to an antibody to mean that it contains two heavy chains andtwo light chains, optionally associated by disulfide bonds as occurswith naturally-produced antibodies. In some embodiments, an antibodyaccording to the present invention is an antibody fragment. As usedherein, an “antibody fragment” includes a portion of an intact antibody,such as, for example, the antigen-binding or variable region of anantibody. Examples of antibody fragments include Fab, Fab′, F(ab′)2, andFv fragments; triabodies; tetrabodies; linear antibodies; single-chainantibody molecules; and multi specific antibodies formed from antibodyfragments. For example, antibody fragments include isolated fragments,“Fv” fragments, consisting of the variable regions of the heavy andlight chains, recombinant single chain polypeptide molecules in whichlight and heavy chain variable regions are connected by a peptide linker(“ScFv proteins”), and minimal recognition units consisting of the aminoacid residues that mimic the hypervariable region. In many embodiments,an antibody fragment contains sufficient sequence of the parent antibodyof which it is a fragment that it binds to the same antigen as does theparent antibody; in some embodiments, a fragment binds to the antigenwith a comparable affinity to that of the parent antibody and/orcompetes with the parent antibody for binding to the antigen. Examplesof antigen binding fragments of an antibody include, but are not limitedto, Fab fragment, Fab′ fragment, F(ab′)2 fragment, scFv fragment, Fvfragment, dsFv diabody, dAb fragment, Fd′ fragment, Fd fragment, and anisolated complementarity determining region (CDR) region.

Approximately or about: As used herein, the term “approximately” or“about,” as applied to one or more values of interest, refers to a valuethat is similar to a stated reference value. In certain embodiments, theterm “approximately” or “about” refers to a range of values that fallwithin 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%,8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greaterthan or less than) of the stated reference value unless otherwise statedor otherwise evident from the context (except where such number wouldexceed 100% of a possible value).

Bioavailability: As used herein, the term “bioavailability” generallyrefers to the percentage of the administered dose that reaches the bloodstream of a subject.

Biologically active: As used herein, the phrase “biologically active”refers to a characteristic of any agent that has activity in abiological system, and particularly in an organism. For instance, anagent that, when administered to an organism, has a biological effect onthat organism, is considered to be biologically active.

Expression: As used herein, “expression” of a nucleic acid sequencerefers to translation of an mRNA into a polypeptide (e.g., heavy chainor light chain of antibody), assemble multiple polypeptides (e.g., heavychain or light chain of antibody) into an intact protein (e.g.,antibody) and/or post-translational modification of a polypeptide orfully assembled protein (e.g., antibody). In this application, the terms“expression” and “production,” and grammatical equivalent, are usedinter-changeably.

Functional: As used herein, a “functional” biological molecule is abiological molecule in a form in which it exhibits a property and/oractivity by which it is characterized.

GC content: As used herein, the “GC content” is the fraction orpercentage of total nucleobase residues in a nucleic acid sequence thatare guanine residues, cytosine residues, or analogs thereof. Forexample, a 100 nt sequence that contains exactly 30 cytosines, exactly30 guanines, exactly one cytosine analog, and exactly one guanine analoghas a GC richness of 62%.

Half-life: As used herein, the term “half-life” is the time required fora quantity such as protein concentration or activity to fall to half ofits value as measured at the beginning of a time period.

Improve, increase, or reduce: As used herein, the terms “improve,”“increase” or “reduce,” or grammatical equivalents, indicate values thatare relative to a baseline measurement, such as a measurement in thesame individual prior to initiation of the treatment described herein,or a measurement in a control subject (or multiple control subject) inthe absence of the treatment described herein. A “control subject” is asubject afflicted with the same form of disease as the subject beingtreated, who is about the same age as the subject being treated.

In Vitro: As used herein, the term “in vitro” refers to events thatoccur in an artificial environment, e.g., in a test tube or reactionvessel, in cell culture, etc., rather than within a multi-cellularorganism.

In Vivo: As used herein, the term “in vivo” refers to events that occurwithin a multi-cellular organism, such as a human and a non-humananimal. In the context of cell-based systems, the term may be used torefer to events that occur within a living cell (as opposed to, forexample, in vitro systems).

Isolated: As used herein, the term “isolated” refers to a substanceand/or entity that has been (1) separated from at least some of thecomponents with which it was associated when initially produced (whetherin nature and/or in an experimental setting), and/or (2) produced,prepared, and/or manufactured by the hand of man. Isolated substancesand/or entities may be separated from about 10%, about 20%, about 30%,about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%,about 98%, about 99%, or more than about 99% of the other componentswith which they were initially associated. In some embodiments, isolatedagents are about 80%, about 85%, about 90%, about 91%, about 92%, about93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%,or more than about 99% pure. As used herein, a substance is “pure” if itis substantially free of other components. As used herein, calculationof percent purity of isolated substances and/or entities should notinclude excipients (e.g., buffer, solvent, water, etc.).

Linker: As used herein, the term “linker” refers to, in a fusionprotein, an amino acid sequence other than that appearing at aparticular position in the natural protein and is generally designed tobe flexible or to interpose a structure, such as an α-helix, between twoprotein moieties. A linker is also referred to as a spacer. A linker ora spacer typically does not have biological function on its own.

Local distribution or delivery: As used herein, the terms “localdistribution,” “local delivery,” or grammatical equivalent, refer totissue specific delivery or distribution. Typically, local distributionor delivery requires a protein (e.g., antibody) encoded by mRNAs betranslated and expressed intracellularly or with limited secretion thatavoids entering the patient's circulation system.

messenger RNA (mRNA): As used herein, the term “messenger RNA (mRNA)”refers to a polynucleotide that encodes at least one polypeptide. mRNAas used herein encompasses both modified and unmodified RNA. mRNA maycontain one or more coding and non-coding regions.

Nucleic acid: As used herein, the term “nucleic acid,” in its broadestsense, refers to any compound and/or substance that is or can beincorporated into a polynucleotide chain. In some embodiments, a nucleicacid is a compound and/or substance that is or can be incorporated intoa polynucleotide chain via a phosphodiester linkage. In someembodiments, “nucleic acid” refers to individual nucleic acid residues(e.g., nucleotides and/or nucleosides). In some embodiments, “nucleicacid” refers to a polynucleotide chain comprising individual nucleicacid residues. In some embodiments, “nucleic acid” encompasses RNA aswell as single and/or double-stranded DNA and/or cDNA. Furthermore, theterms “nucleic acid,” “DNA,” “RNA,” and/or similar terms include nucleicacid analogs, i.e., analogs having other than a phosphodiester backbone.For example, the so-called “peptide nucleic acids,” which are known inthe art and have peptide bonds instead of phosphodiester bonds in thebackbone, are considered within the scope of the present invention. Theterm “nucleotide sequence encoding an amino acid sequence” includes allnucleotide sequences that are degenerate versions of each other and/orencode the same amino acid sequence. Nucleotide sequences that encodeproteins and/or RNA may include introns. Nucleic acids can be purifiedfrom natural sources, produced using recombinant expression systems andoptionally purified, chemically synthesized, etc. Where appropriate,e.g., in the case of chemically synthesized molecules, nucleic acids cancomprise nucleoside analogs such as analogs having chemically modifiedbases or sugars, backbone modifications, etc. A nucleic acid sequence ispresented in the 5′ to 3′ direction unless otherwise indicated. In someembodiments, a nucleic acid is or comprises natural nucleosides (e.g.,adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine,deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs(e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine,3-methyl adenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine,C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine,C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine,8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine);chemically modified bases; biologically modified bases (e.g., methylatedbases); intercalated bases; modified sugars (e.g., 2′-fluororibose,ribose, 2′-deoxyribose, arabinose, and hexose); and/or modifiedphosphate groups (e.g., phosphorothioates and 5′-N-phosphoramiditelinkages). In some embodiments, the present invention is specificallydirected to “unmodified nucleic acids,” meaning nucleic acids (e.g.,polynucleotides and residues, including nucleotides and/or nucleosides)that have not been chemically modified in order to facilitate or achievedelivery.

Patient: As used herein, the term “patient” or “subject” refers to anyorganism to which a provided composition may be administered, e.g., forexperimental, diagnostic, prophylactic, cosmetic, and/or therapeuticpurposes. Typical patients include animals (e.g., mammals such as mice,rats, rabbits, non-human primates, and/or humans). In some embodiments,a patient is a human. A human includes pre and post natal forms.

Pharmaceutically acceptable: The term “pharmaceutically acceptable” asused herein, refers to substances that, within the scope of soundmedical judgment, are suitable for use in contact with the tissues ofhuman beings and animals without excessive toxicity, irritation,allergic response, or other problem or complication, commensurate with areasonable benefit/risk ratio.

Systemic distribution or delivery: As used herein, the terms “systemicdistribution,” “systemic delivery,” or grammatical equivalent, refer toa delivery or distribution mechanism or approach that affect the entirebody or an entire organism. Typically, systemic distribution or deliveryis accomplished via body's circulation system, e.g., blood stream.Compared to the definition of“local distribution or delivery.”

Subject: As used herein, the term “subject” refers to a human or anynon-human animal (e.g., mouse, rat, rabbit, dog, cat, cattle, swine,sheep, horse or primate). A human includes pre- and post-natal forms. Inmany embodiments, a subject is a human being. A subject can be apatient, which refers to a human presenting to a medical provider fordiagnosis or treatment of a disease. The term “subject” is used hereininterchangeably with “individual” or “patient.” A subject can beafflicted with or is susceptible to a disease or disorder but may or maynot display symptoms of the disease or disorder.

Substantially: As used herein, the term “substantially” refers to thequalitative condition of exhibiting total or near-total extent or degreeof a characteristic or property of interest. One of ordinary skill inthe biological arts will understand that biological and chemicalphenomena rarely, if ever, go to completion and/or proceed tocompleteness or achieve or avoid an absolute result. The term“substantially” is therefore used herein to capture the potential lackof completeness inherent in many biological and chemical phenomena.

Target tissues: As used herein, the term “target tissues” refers to anytissue that is affected by a disease to be treated. In some embodiments,target tissues include those tissues that display disease-associatedpathology, symptom, or feature.

Therapeutically effective amount: As used herein, the term“therapeutically effective amount” of a therapeutic agent means anamount that is sufficient, when administered to a subject suffering fromor susceptible to a disease, disorder, and/or condition, to treat,diagnose, prevent, and/or delay the onset of the symptom(s) of thedisease, disorder, and/or condition. It will be appreciated by those ofordinary skill in the art that a therapeutically effective amount istypically administered via a dosing regimen comprising at least one unitdose.

Treating: As used herein, the term “treat,” “treatment,” or “treating”refers to any method used to partially or completely alleviate,ameliorate, relieve, inhibit, prevent, delay onset of, reduce severityof and/or reduce incidence of one or more symptoms or features of aparticular disease, disorder, and/or condition. Treatment may beadministered to a subject who does not exhibit signs of a disease and/orexhibits only early signs of the disease for the purpose of decreasingthe risk of developing pathology associated with the disease.

DETAILED DESCRIPTION

The present invention provides, among other things, methods andcompositions for delivering antibodies in vivo based on mRNA deliverytechnology. In some embodiments, the present invention provides a methodof delivery an antibody by administering to a subject in need ofdelivery one or more mRNAs encoding a heavy chain and a light chain ofthe antibody. In some embodiments, the heavy chain and the light chainof an antibody are delivered by separate mRNAs. In some embodiments, theheavy chain and the light chain of an antibody are delivered by a samemRNA. mRNAs may be delivered as packaged particles (e.g., encapsulatedin liposomes or polymer based vehicles) or unpackaged (i.e., naked).mRNA encoded antibodies may be expressed locally (e.g., in a tissuespecific manner) or systematically in the subject.

Various aspects of the invention are described in detail in thefollowing sections. The use of sections is not meant to limit theinvention. Each section can apply to any aspect of the invention. Inthis application, the use of “or” means “and/or” unless statedotherwise.

mRNA Coded Antibodies

The present invention may be used to deliver any type of antibodies. Asused herein, the term “antibody” encompasses both intact antibody andantibody fragment. Typically, an intact “antibody” is an immunoglobulinthat binds specifically to a particular antigen. An antibody may be amember of any immunoglobulin class, including any of the human classes:IgG, IgM, IgE, IgA, and IgD. Typically, an intact antibody is atetramer. Each tetramer is composed of two identical pairs ofpolypeptide chains, each pair having one “light” (approximately 25 kD)and one “heavy” chain (approximately 50-70 kD). The N-terminus of eachchain defines a variable region of about 100 to 110 or more amino acidsprimarily responsible for antigen recognition. The terms “variable lightchain” (VL) and “variable heavy chain” (VH) refer to these correspondingregions on the light and heavy chain respectively. Each variable regioncan be further subdivided into hypervariable (HV) and framework (FR)regions. The hypervariable regions comprise three areas ofhypervariability sequence called complementarity determining regions(CDR 1, CDR 2 and CDR 3), separated by four framework regions (FR1, FR2,FR2, and FR4) which form a beta-sheet structure and serve as a scaffoldto hold the HV regions in position. The C-terminus of each heavy andlight chain defines a constant region consisting of one domain for thelight chain (CL) and three for the heavy chain (CH1, CH2 and CH3). Alight chain of immunoglobulins can be further differentiated into theisotypes kappa and lambda.

In some embodiments, the terms “intact antibody” or “fully assembledantibody” are used in reference to an antibody that contains two heavychains and two light chains, optionally associated by disulfide bonds asoccurs with naturally-produced antibodies. In some embodiments, anantibody according to the present invention is an antibody fragment.

In some embodiments, the present invention can be used to deliver an“antibody fragment.” As used herein, an “antibody fragment” includes aportion of an intact antibody, such as, for example, the antigen-bindingor variable region of an antibody. Examples of antibody fragmentsinclude Fab, Fab′, F(ab′)₂, and Fv fragments; triabodies; tetrabodies;linear antibodies; single-chain antibody molecules; and multi specificantibodies formed from antibody fragments. For example, antibodyfragments include isolated fragments, “Fv” fragments, consisting of thevariable regions of the heavy and light chains, recombinant single chainpolypeptide molecules in which light and heavy chain variable regionsare connected by a peptide linker (“ScFv proteins”), and minimalrecognition units consisting of the amino acid residues that mimic thehypervariable region. In many embodiments, an antibody fragment containsa sufficient sequence of the parent antibody of which it is a fragmentthat it binds to the same antigen as does the parent antibody; in someembodiments, a fragment binds to the antigen with a comparable affinityto that of the parent antibody and/or competes with the parent antibodyfor binding to the antigen. Examples of antigen binding fragments of anantibody include, but are not limited to, Fab fragment, Fab′ fragment,F(ab′)₂ fragment, scFv fragment, Fv fragment, dsFv diabody, dAbfragment, Fd′ fragment, Fd fragment, and an isolated complementaritydetermining region (CDR).

The present invention may be used to deliver any antibody known in theart and antibodies that can be produced against desired antigens usingstandard methods. The present invention may be used to delivermonoclonal antibodies, polyclonal antibodies, antibody mixtures orcocktails, human or humanized antibodies, chimeric antibodies, orbi-specific antibodies.

Exemplary antibodies include, but are not limited to, anti-chemokine(C—C motif) ligand 2 (CCL2), anti-lysyl oxidase-like-2 (LOXL2),anti-Flt-1, anti-TNF-α, anti-Interleukin-2Rα receptor (CD25),anti-TGF_(β), anti-B-cell activating factor, anti-alpha-4 integrin,anti-BAGE, anti-β-catenin/m, anti-Bcr-abl, anti-C5, anti-CA125,anti-CAMEL, anti-CAP-1, anti-CASP-8, anti-CD4, anti-CD19, anti-CD20,anti-CD22, anti-CD25, anti-CDC27/m, anti-CD 30, anti-CD33, anti-CD52,anti-CD56, anti-CD80, anti-CDK4/m, anti-CEA, anti-CT, anti-CTL4,anti-Cyp-B, anti-DAM, anti-EGFR, anti-ErbB3, anti-ELF2M, anti-EMMPRIN,anti-EpCam, anti-ETV6-AML1, anti-HER2, anti-G250, anti-GAGE, anti-GnT-V,anti-Gp100, anti-HAGE, anti-HER-2/neu, anti-HLA-A*0201-R170I,anti-IGF-1R, anti-IL-2R, anti-IL-5, anti-MC1R, anti-myosin/m, anti-MUC1,anti-MUM-1, -2, -3, anti-proteinase-3, anti-p190 minor bcr-abl,anti-Pml/RARα, anti-PRAMS, anti-PSA, anti-PSM, anti-PSMA, anti-RAGE,anti-RANKL, anti-RU1 or RU2, anti-SAGE, anti-SART-1 or anti-SART-3,anti-survivin, anti-TEL/AML1, anti-TPI/m, anti-TRP-1, anti-TRP-2,anti-TRP-2/INT2, and anti-VEGF or anti-VEGF receptor.

mRNAs Encoding Heavy Chain and Light Chain

According to the present invention, antibodies (e.g., intact antibodiesand antibody fragments) may be produced in a cell or living organismthrough exogenous mRNA translation inside the cell and living organism.In particular, according to the present invention, production of fullyassembled multi-chain antibodies can be accomplished in a cell or livingorganism by delivering exogenous mRNAs encoding a heavy chain and alight chain of the antibody. In some embodiments, a tetramer containingtwo heavy chains and two light chains is produced.

As used herein, the term “heavy chain” encompasses all types ofnaturally-occurring heavy chains of different classes ofimmunoglobulins, including but not limited to, IgM(p), IgD (δ), IgG(γ),IgA(α), and IgE(ε), and biologically active variants thereof. Typically,a heavy chain according to the present invention contains the N-terminalvariable region responsible for antigen recognition, typically includingCDR 1, CDR 2 and CDR 3, separated by four framework regions (FR1, FR2,FR2, and FR4). Typically, the N-terminal variable region contains about100 to 110 or more amino acids. In some embodiments, a heavy chainaccording to the present invention contains one or more of constantdomains (e.g., C_(H)1, C_(H)2, and/or C_(H)3). In some embodiments, anmRNA encoding a heavy chain of an antibody is of or greater than 0.3 kb,0.5 kb, 0.75 kb, 1.0 kb, 1.25 kb, 1.5 kb, 1.75 kb, 2.0 kb, 2.5 kb, 3.0kb, 3.5 kb, 4.0 kb in length.

As used herein, the term “light chain” encompasses all types ofnaturally-occurring light chains of different classes ofimmunoglobulins, including but not limited to K or isotypes, andbiologically active variants thereof. Typically, a light chain accordingto the present invention comprises an N-terminal variable domain(V_(L)). In some embodiments, a light chain according to the presentinvention contains a C-terminal constant domain (C_(L)). In someembodiments, an mRNA encoding a light chain of an antibody is of orgreater than 0.1 kb, 0.2 kb, 0.3 kb, 0.4 kb, 0.5 kb, 0.6 kb, 0.7 kb, 0.8kb, 0.9 kb, 1.0 kb, 1.25 kb, 1.5 kb, 1.75 kb, 2.0 kb, 2.5 kb, or 3.0 kbin length.

Typically, a tetrameric antibody containing two heavy chains and twolight chains encoded by mRNAs, each bonded together by a disulfidebridge.

According to the present invention, a heavy chain and light chain of anantibody may be encoded and delivered by a single mRNA or separatemRNAs. It is contemplated that it may be advantageous to deliver heavychain encoding mRNA and light chain encoding mRNA at varying ratios inorder to optimize production of fully assembled functional antibodies.Thus, in some embodiments, the heavy chain encoding mRNA (also referredto as the first mRNA) and the light chain encoding mRNA (also referredto as the second mRNA) are delivered at a ratio ranging betweenapproximately 10:1 to 1:10 (e.g., between approximately 9:1 to 1:9, 8:1to 1:8, 7:1 to 1:7, 6:1 to 1:6, 5:1 to 1:5, 4:1 to 1:4, 3:1 to 1:3, or2:1 to 1:2). In some embodiments the heavy chain encoding mRNA (alsoreferred to as the first mRNA) and the light chain encoding mRNA (alsoreferred to as the second mRNA) are delivered at a ratio of or greaterthan approximately 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1 or 1:1.In some embodiments, the heavy chain encoding mRNA (also referred to asthe first mRNA) and the light chain encoding mRNA (also referred to asthe second mRNA) are delivered at a ratio of approximately 1:1 (i.e.,equal molar). In some embodiments, the heavy chain encoding mRNA (alsoreferred to as the first mRNA) and the light chain encoding mRNA (alsoreferred to as the second mRNA) are delivered at a ratio other than 1:1(equal molar). For example, the heavy chain encoding mRNA (also referredto as the first mRNA) and the light chain encoding mRNA (also referredto as the second mRNA) are delivered at a ratio greater than 1 (e.g.,ranging between approximately 10:1 to 1:1, 9:1 to 1:1, 8:1 to 1:1, 7:1to 1:1, 6:1 to 1:1, 5:1 to 1:1, 4:1 to 1:1, 3:1 to 1:1, or 2:1 to 1:1).Alternatively, the heavy chain encoding mRNA (also referred to as thefirst mRNA) and the light chain encoding mRNA (also referred to as thesecond mRNA) are delivered at a ratio less than 1 (e.g., ranging betweenapproximately 1:1 to 1:10, 1:1 to 1:9, 1:1 to 1:8, 1:1 to 1:7, 1:1 to1:6, 1:1 to 1:5, 1:1 to 1:4, 1:1 to 1:3, or 1:1 to 1:2).

Signal Peptide

In some embodiments, an mRNA encoding a heavy chain and/or light chainincorporates a nucleotide sequence encoding a signal peptide. As usedherein, the term “signal peptide” refers to a peptide present at a newlysynthesized protein that can target the protein towards the secretorypathway. Typically, the signal peptide is cleaved after translocationinto the endoplasmic reticulum following translation of the mRNA. Signalpeptide is also referred to as signal sequence, leader sequence orleader peptide. Typically, a signal peptide is a short (e.g., 5-30,5-25, 5-20, 5-15, or 5-10 amino acids long) peptide. A signal peptidemay be present at the N-terminus of a newly synthesized protein. Withoutwishing to be bound by any particular theory, the incorporation of asignal peptide encoding sequence on a heavy chain and/or light chainencoding mRNA may facilitate the secretion and/or production of theantibody produced from the mRNA in vivo.

A suitable signal peptide for the present invention can be aheterogeneous sequence derived from various eukaryotic and prokaryoticproteins, in particular secreted proteins. In some embodiments, asuitable signal peptide is a leucine-rich sequence. See Yamamoto Y etal. (1989), Biochemistry, 28:2728-2732, which is incorporated herein byreference. A suitable signal peptide may be derived from a human growthhormone (hGH), serum albumin preproprotein, Ig kappa light chainprecursor, Azurocidin preproprotein, cystatin-S precursor, trypsinogen 2precursor, potassium channel blocker, alpha conotoxin 1p1.3, alphaconotoxin, alfa-galactosidase, cellulose, aspartic proteinasenepenthesin-1, acid chitinase, K28 prepro-toxin, killer toxin zygocinprecursor, and Cholera toxin. Exemplary signal peptide sequences aredescribed in Kober, et al., Biotechnol. Bioeng., 110: 1164-73, 2012,which is incorporated herein by reference.

In some embodiments, a heavy chain and/or light chain encoding mRNA mayincorporate a sequence encoding a signal peptide derived from humangrowth hormone (hGH), or a fragment thereof. A non-limiting nucleotidesequence encoding a hGH signal peptide is show below.

5′ human growth hormone (hGH) sequence (SEQ ID NO: 9):AUGGCCACUGGAUCAAGAACCUCACUGCUGCUCGCUUUUGGACUGCUUUGCCUGCCCUGGUUGCAAGAAGGAUCGGCUUUCCCGACCAUCCCACUCUCCAlternative 5′ human growth hormone (hGH) sequence (SEQ ID NO: 10):AUGGCAACUGGAUCAAGAACCUCCCUCCUGCUCGCAUUCGGCCUGCUCUGUCUCCCAUGGCUCCAAGAAGGAAGCGCGUUCCCCACUAUCCCCCUCUCG

In some embodiments, an mRNA according to the present invention mayincorporate a signal peptide encoding sequence having at least 50%, 55%,60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or moreidentity to SEQ ID NO:9 or SEQ ID NO:10.

Synthesis of mRNA

mRNAs according to the present invention may be synthesized according toany of a variety of known methods. For example, mRNAs according to thepresent invention may be synthesized via in vitro transcription (IVT).Briefly, IVT is typically performed with a linear or circular DNAtemplate containing a promoter, a pool of ribonucleotide triphosphates,a buffer system that may include DTT and magnesium ions, and anappropriate RNA polymerase (e.g., T3, T7 or SP6 RNA polymerase), DNAseI, pyrophosphatase, and/or RNAse inhibitor. The exact conditions willvary according to the specific application.

In some embodiments, for the preparation of antibody-coding mRNAaccording to the invention, a DNA template is transcribed in vitro. Asuitable DNA template typically has a promoter, for example a T3, T7 orSP6 promoter, for in vitro transcription, followed by desired nucleotidesequence for desired antibody encoding (e.g., heavy chain or light chainencoding) mRNA and a termination signal.

Desired antibody encoding (e.g., heavy chain or light chain encoding)mRNA sequence according to the invention may be determined andincorporated into a DNA template using standard methods. For example,starting from a desired amino acid sequence (e.g., a desired heavy chainor light chain sequence), a virtual reverse translation is carried outbased on the degenerated genetic code. Optimization algorithms may thenbe used for selection of suitable codons. Typically, the G/C content canbe optimized to achieve the highest possible G/C content on one hand,taking into the best possible account the frequency of the tRNAsaccording to codon usage on the other hand. The optimized RNA sequencecan be established and displayed, for example, with the aid of anappropriate display device and compared with the original (wild-type)sequence. A secondary structure can also be analyzed to calculatestabilizing and destabilizing properties or, respectively, regions ofthe RNA.

mRNA according to the present invention may be synthesized as unmodifiedor modified mRNA. Typically, mRNAs are modified to enhance stability.Modifications of mRNA can include, for example, modifications of thenucleotides of the RNA. A modified mRNA according to the invention canthus include, for example, backbone modifications, sugar modificationsor base modifications. In some embodiments, antibody encoding mRNAs(e.g., heavy chain and light chain encoding mRNAs) may be synthesizedfrom naturally occurring nucleotides and/or nucleotide analogues(modified nucleotides) including, but not limited to, purines (adenine(A), guanine (G)) or pyrimidines (thymine (T), cytosine (C), uracil(U)), and as modified nucleotides analogues or derivatives of purinesand pyrimidines, such as e.g. 1-methyl-adenine, 2-methyl-adenine,2-methylthio-N-6-isopentenyl-adenine, N6-methyl-adenine,N6-isopentenyl-adenine, 2-thio-cytosine, 3-methyl-cytosine,4-acetyl-cytosine, 5-methyl-cytosine, 2,6-diaminopurine,1-methyl-guanine, 2-methyl-guanine, 2,2-dimethyl-guanine,7-methyl-guanine, inosine, 1-methyl-inosine, pseudouracil (5-uracil),dihydro-uracil, 2-thio-uracil, 4-thio-uracil,5-carboxymethylaminomethyl-2-thio-uracil,5-(carboxyhydroxymethyl)-uracil, 5-fluoro-uracil, 5-bromo-uracil,5-carboxymethylaminomethyl-uracil, 5-methyl-2-thio-uracil,5-methyl-uracil, N-uracil-5-oxyacetic acid methyl ester,5-methylaminomethyl-uracil, 5-methoxyaminomethyl-2-thio-uracil,5′-methoxycarbonylmethyl-uracil, 5-methoxy-uracil, uracil-5-oxyaceticacid methyl ester, uracil-5-oxyacetic acid (v), 1-methyl-pseudouracil,queosine, 13-D-mannosyl-queosine, wybutoxosine, and phosphoramidates,phosphorothioates, peptide nucleotides, methylphosphonates,7-deazaguanosine, 5-methylcytosine and inosine. The preparation of suchanalogues is known to a person skilled in the art e.g. from the U.S.Pat. Nos. 4,373,071, 4,401,796, 4,415,732, 4,458,066, 4,500,707,4,668,777, 4,973,679, 5,047,524, 5,132,418, 5,153,319, 5,262,530 and5,700,642, the disclosure of which is included here in its full scope byreference.

In some embodiments, antibody encoding mRNAs (e.g., heavy chain andlight chain encoding mRNAs) may contain RNA backbone modifications.Typically, a backbone modification is a modification in which thephosphates of the backbone of the nucleotides contained in the RNA aremodified chemically. Exemplary backbone modifications typically include,but are not limited to, modifications from the group consisting ofmethylphosphonates, methylphosphoramidates, phosphoramidates,phosphorothioates (e.g. cytidine 5′-O-(1-thiophosphate)),boranophosphates, positively charged guanidinium groups etc., whichmeans by replacing the phosphodiester linkage by other anionic, cationicor neutral groups.

In some embodiments, antibody encoding mRNAs (e.g., heavy chain andlight chain encoding mRNAs) may contain sugar modifications. A typicalsugar modification is a chemical modification of the sugar of thenucleotides it contains including, but not limited to, sugarmodifications chosen from the group consisting of2′-deoxy-2′-fluoro-oligoribonucleotide (2′-fluoro-2′-deoxycytidine5′-triphosphate, 2′-fluoro-2′-deoxyuridine 5′-triphosphate),2′-deoxy-2′-deamine-oligoribonucleotide (2′-amino-2′-deoxycytidine5′-triphosphate, 2′-amino-2′-deoxyuridine 5′-triphosphate),2′-O-alkyloligoribonucleotide, 2′-deoxy-2′-C-alkyloligoribonucleotide(2′-O-methylcytidine 5′-triphosphate, 2′-methyluridine 5′-triphosphate),2′-C-alkyloligoribonucleotide, and isomers thereof (2′-aracytidine5′-triphosphate, 2′-arauridine 5′-triphosphate), or azidotriphosphates(2′-azido-2′-deoxycytidine 5′-triphosphate, 2′-azido-2′-deoxyuridine5′-triphosphate).

In some embodiments, antibody encoding mRNAs (e.g., heavy chain andlight chain encoding mRNAs) may contain modifications of the bases ofthe nucleotides (base modifications). A modified nucleotide whichcontains a base modification is also called a base-modified nucleotide.Examples of such base-modified nucleotides include, but are not limitedto, 2-amino-6-chloropurine riboside 5′-triphosphate, 2-aminoadenosine5′-triphosphate, 2-thiocytidine 5′-triphosphate, 2-thiouridine5′-triphosphate, 4-thiouridine 5′-triphosphate, 5-aminoallylcytidine5′-triphosphate, 5-aminoallyluridine 5′-triphosphate, 5-bromocytidine5′-triphosphate, 5-bromouridine 5′-triphosphate, 5-iodocytidine5′-triphosphate, 5-iodouridine 5′-triphosphate, 5-methylcytidine5′-triphosphate, 5-methyluridine 5′-triphosphate, 6-azacytidine5′-triphosphate, 6-azauridine 5′-triphosphate, 6-chloropurine riboside5′-triphosphate, 7-deazaadenosine 5′-triphosphate, 7-deazaguanosine5′-triphosphate, 8-azaadenosine 5′-triphosphate, 8-azidoadenosine5′-triphosphate, benzimidazole riboside 5′-triphosphate,N1-methyladenosine 5′-triphosphate, N1-methylguanosine 5′-triphosphate,N6-methyladenosine 5′-triphosphate, O6-methylguanosine 5′-triphosphate,pseudouridine 5′-triphosphate, puromycin 5′-triphosphate or xanthosine5′-triphosphate.

1 Typically, mRNA synthesis includes the addition of a “cap” on theN-terminal (5′) end, and a “tail” on the C-terminal (3′) end. Thepresence of the cap is important in providing resistance to nucleasesfound in most eukaryotic cells. The presence of a “tail” serves toprotect the mRNA from exonuclease degradation.

Thus, in some embodiments, antibody encoding mRNAs (e.g., heavy chainand light chain encoding mRNAs) include a 5′ cap structure. A 5′ cap istypically added as follows: first, an RNA terminal phosphatase removesone of the terminal phosphate groups from the 5′ nucleotide, leaving twoterminal phosphates; guanosine triphosphate (GTP) is then added to theterminal phosphates via a guanylyl transferase, producing a 5′5′5triphosphate linkage; and the 7-nitrogen of guanine is then methylatedby a methyltransferase. Examples of cap structures include, but are notlimited to, m7G(5′)ppp (5′(A,G(5′)ppp(5)A and G(5)ppp(5′G.

In some embodiments, antibody encoding mRNAs (e.g., heavy chain andlight chain encoding mRNAs) include a 3′ poly(A) tail structure. Apoly-A tail on the 3′ terminus of mRNA typically includes about 10 to300 adenosine nucleotides (e.g., about 10 to 200 adenosine nucleotides,about 10 to 175 adenosine nucleotides, about 10 to 150 adenosinenucleotides, about about 10 to 125 adenosine nucleotides, 10 to 100adenosine nucleotides, about 10 to 75 adenosine nucleotides, about 20 to70 adenosine nucleotides, or about 20 to 60 adenosine nucleotides). Insome embodiments, antibody encoding mRNAs (e.g., heavy chain and lightchain encoding mRNAs) include a 3′ poly(C) tail structure. A suitablepoly-C tail on the 3′ terminus of mRNA typically include about 10 to 200cytosine nucleotides (e.g., about 10 to 150 cytosine nucleotides, about10 to 100 cytosine nucleotides, about 20 to 70 cytosine nucleotides,about 20 to 60 cytosine nucleotides, or about 10 to 40 cytosinenucleotides). The poly-C tail may be added to the poly-A tail or maysubstitute the poly-A tail.

In some embodiments, antibody encoding mRNAs (e.g., heavy chain andlight chain encoding mRNAs) include a 5′ and/or 3′ untranslated region.In some embodiments, a 5′ untranslated region includes one or moreelements that affect an mRNA's stability or translation, for example, aniron responsive element. In some embodiments, a 5′ untranslated regionmay be between about 50 and 500 nucleotides in length (e.g., about 50and 400 nucleotides in length, about 50 and 300 nucleotides in length,about 50 and 200 nucleotides in length, or about 50 and 100 nucleotidesin length).

In some embodiments, a 5′ region of antibody encoding mRNAs (e.g., heavychain and light chain encoding mRNAs) includes a sequence encoding asignal peptide, such as those described herein. In particularembodiments, a signal peptide derived from human growth hormone (hGH)(e.g. SEQ ID NO:9) is incorporated in the 5′ region. Typically, a signalpeptide encoding sequence (e.g., hGH signal peptide encoding sequencesuch as SEQ ID NO:9) is linked, directly or indirectly, to the heavychain or light chain encoding sequence at the N-terminus.

Exemplary mRNAs Encoding Heavy Chain and Light Chain of Anti-CCL2

As a non-limiting example, mRNAs encoding the heavy chain and lightchain of an anti-CCL2 antibody are described in Example 1. The heavychain encoding mRNA without and with the 5′ and 3′ UTR sequences areshown below as SEQ ID NO:1 and SEQ ID NO:2, respectively. The lightchain encoding mRNA without and with the 5′ and 3′ UTR sequences areshown below as SEQ ID NO:3 and SEQ ID NO:4, respectively.

Heavy chain anti-CCL2 (HC-αCCL2) mRNA without 5′ and 3′ UTR(SEQ ID NO: 1): AUGGAAUUCGGCCUGAGCUGGCUGUUCCUGGUGGCCAUCCUGAAGGGCGUGCAGUGCCAGGUCCAGCUGGUGCAGUCUGGCGCCGAAGUGAAGAAACCCGGCUCCUCCGUGAAGGUGUCCUGCAAGGCCUCCGGCGGCACCUUCUCCAGCUACGGCAUCUCCUGGGUCCGACAGGCCCCAGGCCAGGGCCUGGAAUGGAUGGGCGGCAUCAUCCCCAUCUUCGGCACCGCCAACUACGCCCAGAAAUUCCAGGGCAGAGUGACCAUCACCGCCGACGAGUCCACCUCCACCGCCUACAUGGAACUGUCCUCCCUGCGGAGCGAGGACACCGCCGUGUACUACUGCGCCAGAUACGACGGCAUCUACGGCGAGCUGGACUUCUGGGGCCAGGGCACCCUGGUCACCGUGUCCUCUGCCAAGACCACCCCCCCCUCCGUGUACCCUCUGGCCCCUGGCUCUGCCGCCCAGACCAACUCUAUGGUCACCCUGGGCUGCCUGGUCAAGGGCUACUUCCCCGAGCCCGUGACCGUGACCUGGAACUCCGGCUCCCUGUCCUCCGGCGUCCACACCUUCCCUGCCGUGCUGCAGUCCGACCUCUACACCCUGUCCAGCAGCGUGACCGUGCCCUCCUCCACCUGGCCCUCCGAGACAGUGACCUGCAACGUGGCCCACCCCGCCUCCAGCACCAAGGUGGACAAGAAAAUCGUGCCCCUGGACUUCGGCUGCAAGCCCUGCAUCUGUACCGUGCCCGAGGUGUCCUCCGUGUUCAUCUUCCCACCCAAGCCCAAGGACGUGCUGACCAUCACACUGACCCCCAAAGUGACCUGCGUGGUGGUGGACAUCUCCAAGGACGACCCCGAGGUGCAGUUCAGUUGGUUCGUGGACGACGUGGAAGUGCACACCGCUCAGACCCAGCCCAGAGAGGAACAGUUCAACUCCACCUUCAGAUCCGUGUCCGAGCUGCCCAUCAUGCACCAGGACUGGCUGAACGGCAAAGAAUUCAAGUCCAGAGUGAACUCCGCCGCCUUCCCAGCCCCCAUCGAAAAGACCAUCUCCAAGACCAAGGGCAGACCCAAGGCCCCCCAGGUCUACACCAUCCCCCCACCCAAAGAACAGAUGGCCAAGGACAAGGUGUCCCUGACCUGCAUGAUCACCGAUUUCUUCCCAGAGGACAUCACCGUGGAAUGGCAGUGGAACGGCCAGCCCGCCGAGAACUACAAGAACACCCAGCCCAUCAUGGACACCGACGGCUCCUACUUCGUGUACUCCAAGCUGAACGUGCAGAAGUCCAACUGGGAGGCCGGCAACACCUUCACCUGUAGCGUGCUGCACGAGGGCCUGCACAACCACCACACCGAGAAGUCCCUGUCCCAC UCCCCCGGCAAGUGAHeavy chain anti-CCL2 (HC-αCCL2) mRNA with 5′ and 3′ UTR (SEQ ID NO: 2):(The 5′ and 3′ UTR sequences are underlined)GGACAGAUCGCCUGGAGACGCCAUCCACGCUGUUUUGACCUCCAUAGAAGACACCGGGACCGAUCCAGCCUCCGCGGCCGGGAACGGUGCAUUGGAACGCGGAUUCCCCGUGCCAAGAGUGACUCACCGUCCUUGACACGAUGGAAUUCGGCCUGAGCUGGCUGUUCCUGGUGGCCAUCCUGAAGGGCGUGCAGUGCCAGGUCCAGCUGGUGCAGUCUGGCGCCGAAGUGAAGAAACCCGGCUCCUCCGUGAAGGUGUCCUGCAAGGCCUCCGGCGGCACCUUCUCCAGCUACGGCAUCUCCUGGGUCCGACAGGCCCCAGGCCAGGGCCUGGAAUGGAUGGGCGGCAUCAUCCCCAUCUUCGGCACCGCCAACUACGCCCAGAAAUUCCAGGGCAGAGUGACCAUCACCGCCGACGAGUCCACCUCCACCGCCUACAUGGAACUGUCCUCCCUGCGGAGCGAGGACACCGCCGUGUACUACUGCGCCAGAUACCACGGCAUCUACGGCGAGCUGGACUUCUGGGGCCAGGGCACCCUGGUCACCGUGUCCUCUGCCAAGACCACCCCCCCCUCCGUGUACCCUCUGGCCCCUGGCUCUGCCGCCCAGACCAACUCUAUGGUCACCCUGGGCUGCCUGGUCAAGGGCUACUUCCCCGAGCCCGUGACCGUGACCUGGAACUCCGGCUCCCUGUCCUCCGGCGUGCACACCUUCCCUGCCGUGCUGCAGUCCGACCUCUACACCCUGUCCAGCAGCGUGACCGUGCCCUCCUCCACCUGGCCCUCCGAGACAGUGACCUGCAACGUGGCCCACCCCGCCUCCAGCACCAAGGUGGACAAGAAAAUCGUGCCCCGGGACUGCGGCUGCAAGCCCUGCAUCUGUACCGUGCCCGAGGUGUCCUCCGUGUUCAUCUUCCCACCCAAGCCCAAGGACGUGCUGACCAUCACACUGACCCCCAAAGUGACCUGCGUGGUGGUGGACAUCUCCAAGGACGACCCCGAGGUGCAGUUCAGUUGGUUCGUGGACGACGUGGAAGUGCACACCGCUCAGACCCAGCCCAGAGAGGAACAGUUCAACUCCACCUUCAGAUCCGUGUCCGAGCUGCCCAUCAUGCACCAGGACUGGCUGAACGGCAAAGAAUUCAAGUGCAGAGUGAACUCCGCCGCCUUCCCAGCCCCCAUCGAAAAGACCAUCUCCAAGACCAAGGGCAGACCCAAGGCCCCCCAGGUCUACACCAUCCCCCCACCCAAAGAACAGAUGGCCAAGGACAAGGUGUCCCUGACCUGCAUGAUCACCGAUUUCUUCCCAGAGGACAUCACCGUGGAAUGGCAGUGCAACGGCCAGCCCGCCGAGAACUACAAGAACACCCAGCCCAUCAUGGACACCGACGGCUCCUACUUCGUGUACUCCAAGCUGAACGUGCAGAAGUCCAACUGGGAGGCCGGCAACACCUUCACCUGUAGCGUGCUGCACGAGGGCCUGCACAACCACCACACCGAGAAGUCCCUGUCCCACUCCCCCGGCAAGUGACGGGUGGCAUCCCUGUGACCCCUCCCCAGUGCCUCUCCUGGCCCUGGAAGUUGCCACUCCAGUGCCCACCAGCCUUGUCCUAAUAAAAUUAAGUUGCAUCAAGCULight chain anti-CCL2 (LC-αCCL2) mRNA without 5′ and 3′ UTR (SEQ ID NO: 3):AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUGGCUGCCUGAUACCACCGGCGAAAUCGUGCUGACCCAGUCCCCCGCCACCCUGUCUCUGAGCCCUGGCGAGAGAGCCACCCUGAGCUGCAGAGCCUCCCAGUCCGUGUCCGACGCCUACCUGGCCUGGUAUCAGCAGAAGCCCGGCCAGGCCCCUCGGCUGCUGAUCUACGACGCCUCCUCUAGAGCCACCGGCGUGCCCGCCAGAUUCUCCGGCUCUGGCUCUGGCACCGACUUCACCCUGACCAUCUCCAGCCUGGAACCCGAGGACUUCGCCGUGUACUACUGCCACCAGUACAUCCAGCUGCACAGCUUCACCUUCGGCCAGGGCACCAAGGUGGAAAUCAAGGCCGAUGCCGCCCCUACCGUGUCCAUCUUCCCACCCUCCAGCGAGCAGCUGACCUCUGGCGGCGCUUCCGUCGUGUGCUUCCUGAACAACUUCUACCCCAAGGACAUCAACGUGAAGUGGAAGAUCGACGGCUCCGAGCGGCAGAACGGCGUGCUGAACUCCUGGACCGACCAGGACUCCAAGGACAGCACCUACUCCAUGUCCUCCACCCUGACCCUGACCAAGGACGAGUACGAGCGGCACAACUCCUAUACCUGCGAGGCCACCCACAAGACCUCCACCUCCCCCAUCGUGAAGUCCUUCAACCGGAACGAGUGCUGALight chain anti-CCL2 (LC-αCCL2) mRNA with 5′ and 3′ UTR (SEQ ID NO: 4):(The 5′ and 3′ UTR sequences are underlined)GGACAGAUCGCCUGGAGACGCCAUCCACGCUGUUUUGACCUCCAUAGAAGACACCGGGACCGAUCCAGCCUCCGCGGCCGGGAACGGUGCAUUGGAACGCGGAUUCCCCGUGCCAAGAGUGACUCACCGUCCUUGACACGAUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUGGCUGCCUGAUACCACCGGCGAAAUCGUGCUGACCCAGUCCCCCGCCACCCUGUCUCUGAGCCCUGGCGAGAGAGCCACCCUGAGCUGCAGAGCCUCCVAGUCCGUGUCCGACGCCUACCUGGCCUGGUAUCAGCAGAAGCCCGGCCAGGCCCCUCGGCUGCUGAUCUACGACGCCUCCUCUAGAGCCACCGGCGUGCCCGCCAGAUUCUCCGGCUCUGGCUCUGGCACCGACUUCACCCUGACCAUCUCCAGCCUGGAACCCGAGGACUUCGCCGUGUACUACUGCCACCAGUACAUCCAGCUGCACAGCUUCACCUUCGGCCAGGGCACCAAGGUGGAAAUCAAGGCCGAUGCCGCCCCUACCGUGUCCAUCUUCCCACCCUCCAGCGAGCAGCUGACCUCUGGCGGCGCUUCCGUCGUGUGCUUCCUGAACAACUUCUACCCCAAGGACAUCAACGUGAAGUGGAAGAUCGACGGCUCCGAGCGGCAGAACGGCGUGCUGAACUCCUGGACCGACCAGGACUCCAAGGACAGCACCUACUCCAUGUCCUCCACCCUGACCCUGACCAAGGACGAGUACGAGCGGCACAACUCCUAUACCUGCGAGGCCACCCACAAGACCUCCACCUCCCCCAUCGUGAAGUCCUUCAACCGGAACGAGUGCUGACGGGUGGCAUCCCUGUGACCCCUCCCCAGUGCCUCUCCUGGCCCUGGAAGUUGCCACUCCAGUGCCCACCAGCCUUGUCCUAAUAAAAUUAAGUUGCAUCAAGCU

Among other things, the present invention also provides mRNAs encoding aheavy chain and light chain of an anti-CCL2 antibody substantiallyidentical or similar to the sequences described herein. In someembodiments, an mRNA encoding the heavy chain of an anti-CCL2 antibodyhas a nucleotide sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%,85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identicalto SEQ ID NO:1 or SEQ ID NO:2 as described herein. In some embodiments,an mRNA encoding the heavy chain of an anti-CCL2 antibody has anucleotide sequence encoding an amino acid sequence at least 50%, 55%,60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, 99% or more identical or homologous to SEQ ID NO:1 as describedherein. In some embodiments, an mRNA encoding the light chain of ananti-CCL2 antibody has a nucleotide sequence at least 50%, 55%, 60%,65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,99% or more identical to SEQ ID NO:3 or SEQ ID NO:4 as described herein.In some embodiments, an mRNA encoding the light chain of an anti-CCL2antibody has a nucleotide sequence encoding an amino acid sequence atleast 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%,95%, 96%, 97%, 98%, 99% or more identical or homologous to SEQ ID NO:3as described herein.

In some embodiments, mRNA provided herein contains one or more modifiednucleotides such as those described herein. In some embodiments, an mRNAencoding the heavy chain or light chain of an anti-CCL2 antibody maycontain at least 10%, at least 20%, at least 30%, at least 40%, at least50%, at least 60%, at least 70%, at least 75%, at least 80%, at least85%, at least 90%, or at least 95% of modified nucleotides of allmodifiable nucleotides of the sequence.

Exemplary mRNAs Encoding Heavy Chain and Light  Chain of anti-VEGFHeavy chain anti-VEGF (HC-αVEGF) mRNA without 5′ and 3′ UTR (SEQ ID NO: 5):AUGGCAACUGGAUCAAGAACCUCCCUCCUGCUCGCAUUCGGCCUGCUCUGUCUCCCAUGGCUCCAAGAAGGAAGCGCGUUCCCCACUAUCCCCCUCUCGGAGGUUCAGCUGGUCGAAAGCGGGGGCGGCCUCGUCCAGCCAGGUGGAUCCCUCCGCCUGAGCUGCGCCGCGUCCGGAUACACUUUCACCAACUACGGCAUGAACUGGGUCCGCCAGGCGCCGGGAAAGGGACUGGAAUGGGUCGGCUGGAUCAAUACCUACACUGGAGAGCCUACCUACGCCGCUGACUUUAAGAGGCGGUUCACUUUCUCACUGGAUACUUCCAAGUCAACCGCUUACCUUCAGAUGAAUUCCCUGCGCGCCGAGGAUACCGCAGUGUAUUACUGCGCCAAAUACCCGCAUUACUACGGCUCCAGCCACUGGUACUUUGACGUGUGGGGUCAAGGAACCCUGGUGACUGUGUCGUCCGCUUCCACCAAGGGACCAAGCGUGUUUCCACUCGCCCCGAGCUCAAAAUCGACGUCGGGAGGUACUGCCGCACUGGGGUGCUUGGUCAAGGACUACUUUCCAGAGCCGGUGACUGUUUCCUGGAACAGCGGAGCGCUCACCUCGGGCGUGCACACCUUCCCUGCGGUGUUGCAGUCAUCUGGACUGUACUCGCUGUCCAGCGUGGUCACGGUCCCGAGCUCGUCGCUCGGGACCCAAACCUACAUUUGCAAUGUCAACCACAAGCCAUCGAACACCAAAGUCGACAAGAAGGUGGAACCGAAGUCGUGCGACAAGACUCAUACGUGCCCACCGUGUCCGGCUCCGGAACUGUUGGGGGGCCCCUCCGUGUUCCUUUUCCCGCCAAAGCCUAAGGACACUCUCAUGAUCUCACGGACGCCAGAAGUGACCUGUGUGGUCGUGGAUGUGUCACAUGAGGAUCCGGAAGUCAAAUUCAACUGGUAUGUGGACGGGGUGGAAGUGCAUAAUGCCAAAACCAAACCUCGCGAGGAGCAGUACAACUCAACCUACCGGGUGGUGUCCGUGCUGACUGUGCUGCACCAGGACUGGCUGAAUGGAAAGGAGUACAAAUGCAAGGUCAGCAACAAGGCCCUUCCCGCCCCAAUCGAAAAGACGAUCUCGAAGGCCAAAGGUCAGCCGCGAGAGCCUCAAGUGUACACUCUGCCGCCGUCAAGAGAAGAAAUGACUAAGAACCAAGUUUCCCUCACUUGCCUGGUGAAGGGCUUCUACCCCAGCGACAUCGCAGUGGAAUGGGAGAGCAACGGACAGCCGGAAAACAACUAUAAGACCACCCCUCCUGUGUUGGACUCGGAUGGUUCCUUCUUCCUUUACAGCAAGCUGACCGUGGAUAAAUCGCGGUGGCAGCAAGGAAAUGUGUUUUCAUGCUCAGUCAUGCACGAGGCGCUGCACAAUCACUACACUCAGAAGUCCCUGUCGCUGUCGC CAGGAAAAUAA Heavy chain anti-VEGF (HC-αVEGF) mRNA with 5′ and 3′ UTR (SEQ ID NO: 6): (The 5′ and 3′ UTR sequences are underlined,   signal peptide sequences are italicized and bolded)GGACAGAUCGCCUGGAGACGCCAUCCACGCUGUUUUGACCUCCAUAGAAGACACCGGGACCGAUCCAGCCUCCGCGGCCGGGAACGGUGCAUUGGAACGC

GGUCGAAAGCGGGGGCGGCCUCGUCCAGCCAGGUGGAUCCCUCCGCCUGAGCUGCGCCGCGUCCGGAUACACUUUCACCAACUACGGCAUGAACUGGGUCCGCCAGGCGCCGGGAAAGGGACUGGAAUGGGUCGGCUGGAUCAAUACCUACACUGGAGAGCCUACCUACGCCGCUGACUUUAAGAGGCGGUUCACUUUCUCACUGGAUACUUCCAAGUCAACCGCUUACCUUCAGAUGAAUUCCCUGCGCGCCGAGGAUACCGCAGUGUAUUACUGCGCCAAAUACCCGCAUUACUACGGCUCCAGCCACUGGUACUUUGACGUGUGGGGUCAAGGAACCCUGGUGACUGUGUCGUCCGCUUCCACCAAGGGACCAAGCGUGUUUCCACUCGCCCCGAGCUCAAAAUCGACGUCGGGAGGUACUGCCGCACUGGGGUGCUUGGUCAAGGACUACUUUCCAGAGCCGGUGACUGUUUCCUGGAACAGCGGAGCGCUCACCUCGGGCGUGCACACCUUCCCUGCGGUGUUGCAGUCAUCUGGACUGUACUCGCUGUCCAGCGUGGUCACGGUCCCGAGCUCGUCGCUCGGGACCCAAACCUACAUUUGCAAUGUCAACCACAAGCCAUCGAACACCAAAGUCGACAAGAAGGUGGAACCGAAGUCGUGCGACAAGACUCAUACGUGCCCACCGUGUCCGGCUCCGGAACUGUUGGGGGGCCCCUCCGUGUUCCUUUUCCCGCCAAAGCCUAAGGACACUCUCAUGAUCUCACGGACGCCAGAAGUGACCUGUGUGGUCGUGGAUGUGUCACAUGAGGAUCCGGAAGUCAAAUUCAACUGGUAUGUGGACGGGGUGGAAGUGCAUAAUGCCAAAACCAAACCUCGCGAGGAGCAGUACAACUCAACCUACCGGGUGGUGUCCGUGCUGACUGUGCUGCACCAGGACUGGCUGAAUGGAAAGGAGUACAAAUGCAAGGUCAGCAACAAGGCCCUUCCCGCCCCAAUCGAAAAGACGAUCUCGAAGGCCAAAGGUCAGCCGCGAGAGCCUCAAGUGUACACUCUGCCGCCGUCAAGAGAAGAAAUGACUAAGAACCAAGUUUCCCUCACUUGCCUGGUGAAGGGCUUCUACCCCAGCGACAUCGCAGUGGAAUGGGAGAGCAACGGACAGCCGGAAAACAACUAUAAGACCACCCCUCCUGUGUUGGACUCGGAUGGUUCCUUCUUCCUUUACAGCAAGCUGACCGUGGAUAAAUCGCGGUGGCAGCAAGGAAAUGUGUUUUCAUGCUCAGUCAUGCACGAGGCGCUGCACAAUCACUACACUCAGAAGUCCCUGUCGCUGUCGCCAGGAAAAUAACGGGUGGCAUCCCUGUGACCCCUCCCCAGUGCCUCUCCUGGCCCUGGAAGUUGCCACUCCAGUGCCCACCAGCCUUGUCCUAAUAAAAUUAAGUUGCAU CAAGCULight chain anti-VEGF (HC-αVEGF) mRNA without 5′ and 3′ UTR (SEQ ID NO: 7):AUGGCCACUGGAUCAAGAACCUCACUGCUGCUCGCUUUUGGACUGCUUUGCCUGCCCUGGUUGCAAGAAGGAUCGGCUUUCCCGACCAUCCCACUCUCCGACAUUCAAAUGACGCAGUCCCCAUCGAGCCUCUCAGCAUCAGUGGGGGAUCGCGUGACUAUCACUUGCUCGGCGAGCCAGGAUAUCAGCAAUUACCUGAACUGGUAUCAGCAAAAGCCUGGAAAGGCACCGAAGGUGCUGAUCUACUUCACCUCAAGCCUCCAUUCGGGUGUCCCGUCCCGCUUCAGCGGCUCCGGCUCAGGCACUGACUUCACCCUGACUAUCUCCUCGCUGCAACCGGAAGAUUUCGCCACUUACUACUGUCAGCAGUACUCCACCGUGCCUUGGACGUUCGGACAGGGAACCAAAGUUGAGAUUAAGCGGACGGUCGCGGCCCCCUCCGUGUUUAUCUUUCCGCCUUCGGACGAGCAGCUGAAGUCGGGAACCGCCUCUGUCGUGUGCCUCCUGAACAACUUCUACCCGCGGGAAGCCAAGGUGCAGUGGAAAGUGG AUAACGCGCUUCAGAGCGGCAAUUCGCAAGAGUCCGUGACCGAAGAGGACUCGAAGGACUCAACCUACUCCCUCAGCUCAACCCUCACUUUGUCGAAGGCCGACUACGAGAAGCACAAAGUCUACGCAUGCGAAGUCACCCACCAGGGUCUGUCGAGCCCAGUGACUAAAUCCUUCAAUAGGGGGGAAUGUUAA Light chain anti-VEGF (HC-αVEGF) mRNA with 5′ and 3′ UTR (SEQ ID NO: 8): (The 5′ and 3′ UTR sequences are underlined,   signal peptide sequences are italicized and bolded)GGACAGAUCGCCUGGAGACGCCAUCCACGCUGUUUUGACCUCCAUAGAAGACACCGGGACCGAUCCAGCCUCCGCGGCCGGGAACGGUGCAUUGGAACGC

GACGCAGUCCCCAUCGAGCCUCUCAGCAUCAGUGGGGGAUCGCGUGACUAUCACUUGCUCGGCGAGCCAGGAUAUCAGCAAUUACCUGAACUGGUAUCAGCAAAAGCCUGGAAAGGCACCGAAGGUGCUGAUCUACUUCACCUCAAGCCUCCAUUCGGGUGUCCCGUCCCGCUUCAGCGGCUCCGGCUCAGGCACUGACUUCACCCUGACUAUCUCCUCGCUGCAACCGGAAGAUUUCGCCACUUACUACUGUCAGCAGUACUCCACCGUGCCUUGGACGUUCGGACAGGGAACCAAAGU UGAGAUUAAGCGGACGGUCGCGGCCCCCUCCGUGUUUAUCUUUCCGCCUUCGGACGAGCAGCUGAAGUCGGGAACCGCCUCUGUCGUGUGCCUCCUGAACAACUUCUACCCGCGGGAAGCCAAGGUGCAGUGGAAAGUGGAUAACGCGCUUCAGAGCGGCAAUUCGCAAGAGUCCGUGACCGAAGAGGACUCGAAGGACUCAACCUACUCCCUCAGCUCAACCCUCACUUUGUCGAAGGCCGACUACGAGAAGCACAAAGUCUACGCAUGCGAAGUCACCCACCAGGGUCUGUCGAGCCCAGUGACUAAAUCCUUCAAUAGGGGGGAAUGUUAACGGGUGGCAUCCCUGUGACCCCUCCCCAGUGCCUCUCCUGGCCCUGGAAGUUGCCACUCCAGUGCCCACCAGCCUUGUCCUAAUAAAAUUAAGUUGCAUCAAGCU

Among other things, the present invention also provides mRNAs encoding aheavy chain and light chain of an anti-VEGF antibody substantiallyidentical or similar to the sequences described herein. In someembodiments, an mRNA encoding the heavy chain of an anti-VEGF antibodyhas a nucleotide sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%,85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identicalto SEQ ID NO:5 or SEQ ID NO:6 as described herein. In some embodiments,an mRNA encoding the heavy chain of an anti-VEGF antibody has anucleotide sequence encoding an amino acid sequence at least 50%, 55%,60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, 99% or more identical or homologous to SEQ ID NO:5 as describedherein. In some embodiments, an mRNA encoding the light chain of ananti-VEGF antibody has a nucleotide sequence at least 50%/o, 55%, 60%,65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,99% or more identical to SEQ ID NO:7 or SEQ ID NO:8 as described herein.In some embodiments, an mRNA encoding the light chain of an anti-VEGFantibody has a nucleotide sequence encoding an amino acid sequence atleast 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%,95%, 96%, 97%, 98%, 99% or more identical or homologous to SEQ ID NO:7as described herein.

In some embodiments, mRNA provided herein contains one or more modifiednucleotides such as those described herein. In some embodiments, an mRNAencoding the heavy chain or light chain of an anti-VEGF antibody maycontain at least 10%, at least 20%, at least 30%, at least 40%, at least50%, at least 60%, at least 70%, at least 75%, at least 80%, at least85%, at least 90%, or at least 95% of modified nucleotides of allmodifiable nucleotides of the sequence.

As used herein, the term “identity” refers to the overall relatednessbetween polymeric molecules, e.g., between nucleic acid molecules (e.g.,DNA molecules and/or RNA molecules) and/or between polypeptidemolecules. Calculation of the percent identity of two nucleic acidsequences, for example, can be performed by aligning the two sequencesfor optimal comparison purposes (e.g., gaps can be introduced in one orboth of a first and a second nucleic acid sequences for optimalalignment and non-identical sequences can be disregarded for comparisonpurposes). In certain embodiments, the length of a sequence aligned forcomparison purposes is at least 30%, at least 40%, at least 50%, atleast 60%, at least 70%, at least 80%, at least 90%, at least 95%, orsubstantially 100% of the length of the reference sequence. Thenucleotides at corresponding nucleotide positions are then compared.When a position in the first sequence is occupied by the same nucleotideas the corresponding position in the second sequence, then the moleculesare identical at that position. The percent identity between the twosequences is a function of the number of identical positions shared bythe sequences, taking into account the number of gaps, and the length ofeach gap, which needs to be introduced for optimal alignment of the twosequences. The comparison of sequences and determination of percentidentity between two sequences can be accomplished using a mathematicalalgorithm. For example, the percent identity between two nucleotidesequences can be determined using the algorithm of Meyers and Miller(CABIOS, 1989, 4: 11-17), which has been incorporated into the ALIGNprogram (version 2.0) using a PAM120 weight residue table, a gap lengthpenalty of 12 and a gap penalty of 4. The percent identity between twonucleotide sequences can, alternatively, be determined using the GAPprogram in the GCG software package using an NWSgapdna.CMP matrix.

Delivery Vehicles

According to the present invention, antibody encoding mRNAs (e.g., heavychain and light chain encoding mRNAs) described herein may be deliveredas naked RNA (unpackaged) or via delivery vehicles. As used herein, theterms “delivery vehicle,” “transfer vehicle,” or grammatical equivalent,are used interchangeably.

In some embodiments, mRNAs encoding a heavy chain and a light chain ofan antibody may be delivered via a single delivery vehicle. In someembodiments, mRNAs encoding a heavy chain and a light chain of anantibody may be delivered via separate delivery vehicles. For example,mRNAs encoding a heavy chain and a light chain of an antibody may bepackaged separately but delivered simultaneously. Alternatively, mRNAsencoding a heavy chain and a light chain of an antibody may be packagedseparately and delivered sequentially.

According to various embodiments, suitable delivery vehicles include,but are not limited to polymer based carriers, such as polyethyleneimine(PEI), lipid nanoparticles and liposomes, nanoliposomes,ceramide-containing nanoliposomes, proteoliposomes, both natural andsynthetically-derived exosomes, natural, synthetic and semi-syntheticlamellar bodies, nanoparticulates, calcium phosphor-silicatenanoparticulates, calcium phosphate nanoparticulates, silicon dioxidenanoparticulates, nanocrystalline particulates, semiconductornanoparticulates, poly(D-arginine), sol-gels, nanodendrimers,starch-based delivery systems, micelles, emulsions, niosomes,multi-domain-block polymers (vinyl polymers, polypropyl acrylic acidpolymers, dynamic polyconjugates), dry powder formulations, plasmids,viruses, calcium phosphate nucleotides, aptamers, peptides and othervectorial tags.

Liposomal Delivery Vehicles

In some embodiments, a suitable delivery vehicle is a liposomal deliveryvehicle, e.g. a lipid nanoparticle. As used herein, liposomal deliveryvehicles, e.g. lipid nanoparticles, are usually characterized asmicroscopic vesicles having an interior aqua space sequestered from anouter medium by a membrane of one or more bilayers. Bilayer membranes ofliposomes are typically formed by amphiphilic molecules, such as lipidsof synthetic or natural origin that comprise spatially separatedhydrophilic and hydrophobic domains (Lasic, Trends Biotechnol., 16:307-321, 1998). Bilayer membranes of the liposomes can also be formed byamphophilic polymers and surfactants (e.g., polymerosomes, niosomes,etc.). In the context of the present invention, a liposomal deliveryvehicle typically serves to transport a desired mRNA to a target cell ortissue. The process of incorporation of a desired mRNA into a liposomeis often referred to as “loading”. Exemplary methods are described inLasic, et al., FEBS Lett., 312: 255-258, 1992, which is incorporatedherein by reference. The liposome-incorporated nucleic acids may becompletely or partially located in the interior space of the liposome,within the bilayer membrane of the liposome, or associated with theexterior surface of the liposome membrane. The incorporation of anucleic acid into liposomes is also referred to herein as“encapsulation” wherein the nucleic acid is entirely contained withinthe interior space of the liposome. The purpose of incorporating a mRNAinto a transfer vehicle, such as a liposome, is often to protect thenucleic acid from an environment which may contain enzymes or chemicalsthat degrade nucleic acids and/or systems or receptors that cause therapid excretion of the nucleic acids. Accordingly, in some embodiments,a suitable delivery vehicle is capable of enhancing the stability of themRNA contained therein and/or facilitate the delivery of mRNA to thetarget cell or tissue.

In some embodiments, a suitable delivery vehicle is formulated as alipid nanoparticle. As used herein, the phrase “lipid nanoparticle”refers to a delivery vehicle comprising one or more lipids (e.g.,cationic lipids, non-cationic lipids, cholesterol-based lipids, andPEG-modified lipids). The contemplated lipid nanoparticles may beprepared by including multi-component lipid mixtures of varying ratiosemploying one or more cationic lipids, non-cationic lipids,cholesterol-based lipids, and PEG-modified lipids. Examples of suitablelipids include, for example, the phosphatidyl compounds (e.g.,phosphatidylglycerol, phosphatidylcholine, phosphatidylserine,phosphatidylethanolamine, sphingolipids, cerebrosides, andgangliosides).

In certain embodiments of the invention, the carrier is formulated usinga polymer as a carrier, alone or in combination with other carriers.Suitable polymers may include, for example, polyacrylates,polyalkycyanoacrylates, polylactide, polylactide-polyglycolidecopolymers, polycaprolactones, dextran, albumin, gelatin, alginate,collagen, chitosan, cyclodextrins, protamine, PEGylated protamine, PLL,PEGylated PLL and polyethylenimine (PEI). When PEI is present, it may bebranched PEI of a molecular weight ranging from 10 to 40 kDA, e.g., 25kDa branched PEI (Sigma #408727).

In some embodiments, a suitable delivery vehicle contains a cationiclipid. As used herein, the phrase “cationic lipid” refers to any of anumber of lipid species that have a net positive charge at a selectedpH, such as physiological pH. Several cationic lipids have beendescribed in the literature, many of which are commercially available.Particularly suitable cationic lipids for use in the compositions andmethods of the invention include those described in international patentpublications WO 2010/053572 (and particularly, CI 2-200 described atparagraph [00225]) and WO 2012/170930, both of which are incorporatedherein by reference. In certain embodiments, the compositions andmethods of the invention employ a lipid nanoparticles comprising anionizable cationic lipid described in U.S. provisional patentapplication 61/617,468, filed Mar. 29, 2012 (incorporated herein byreference), such as, e.g, (15Z, 18Z)—N,N-dimethyl-6-(9Z,12Z)-octadeca-9, 12-dien-1-yl)tetracosa-15,18-dien-1-amine (HGT5000),(15Z, 18Z)—N,N-dimethyl-6-((9Z, 12Z)-octadeca-9,12-dien-1-yl)tetracosa-4,15,18-trien-1-amine (HGT5001), and(15Z,18Z)—N,N-dimethyl-6-((9Z, 12Z)-octadeca-9,12-dien-1-yl)tetracosa-5, 15, 18-trien-1-amine (HGT5002).

In some embodiments, the cationic lipidN-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride or “DOTMA”is used. (Feigner et al. (Proc. Nat'l Acad. Sci. 84, 7413 (1987); U.S.Pat. No. 4,897,355). DOTMA can be formulated alone or can be combinedwith the neutral lipid, dioleoylphosphatidyl-ethanolamine or “DOPE” orother cationic or non-cationic lipids into a liposomal transfer vehicleor a lipid nanoparticle, and such liposomes can be used to enhance thedelivery of nucleic acids into target cells. Other suitable cationiclipids include, for example, 5-carboxyspermylglycinedioctadecylamide or“DOGS,”2,3-dioleyloxy-N-[2(spermine-carboxamido)ethyl]-N,N-dimethyl-1-propanaminiumor “DOSPA” (Behr et al. Proc. Nat'l Acad. Sci. 86, 6982 (1989); U.S.Pat. Nos. 5,171,678; 5,334,761), 1,2-Dioleoyl-3-Dimethylammonium-Propaneor “DODAP”, 1,2-Dioleoyl-3-Trimethylammonium-Propane or “DOTAP”.Contemplated cationic lipids also include1,2-distearyloxy-N,N-dimethyl-3-aminopropane or “DSDMA”,1,2-dioleyloxy-N,N-dimethyl-3-aminopropane or “DODMA”,1,2-dilinoleyloxy-N,N-dimethyl-3-aminopropane or “DLinDMA”,1,2-dilinolenyloxy-N,N-dimethyl-3-aminopropane or “DLenDMA”,N-dioleyl-N,N-dimethylammonium chloride or “DODAC”,N,N-distearyl-N,N-dimethylarnmonium bromide or “DDAB”,N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammoniumbromide or “DMRIE”,3-dimethylamino-2-(cholest-5-en-3-beta-oxybutan-4-oxy)-1-(cis,cis-9,12-octadecadienoxy)propaneor “CLinDMA”, 2-[5′-(cholest-5-en-3-beta-oxy)-3′-oxapentoxy)-3-dimethy1-1-(cis,cis-9′, I1-2′-octadecadienoxy)propane or “CpLinDMA”,N,N-dimethyl-3,4-dioleyloxybenzylamine or “DMOBA”,1,2-N,N′-dioleylcarbamyl-3-dimethylaminopropane or “DOcarbDAP”,2,3-Dilinoleoyloxy-N,N-dimethylpropylamine or “DLinDAP”,1,2-N,N′-Dilinoleylcarbamyl-3-dimethylaminopropane or “DLincarbDAP”,1,2-Dilinoleoylcarbamyl-3-dimethylaminopropane or “DLinCDAP”,2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane or “DLin- -DMA”,2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane or“DLin-K-XTC2-DMA”, and2-(2,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)-1,3-dioxolan-4-yl)-N,N-dimethylethanamine(DLin-KC2-DMA)) (See, WO 2010/042877; Semple et al., Nature Biotech. 28:172-176 (2010)), or mixtures thereof. (Heyes, J., et al., J ControlledRelease 107: 276-287 (2005); Morrissey, D V., et al., Nat. Biotechnol.23(8): 1003-1007 (2005); PCT Publication WO2005/121348A1).

In some embodiments, one or more of the cationic lipids present in sucha composition comprise at least one of an imidazole, dialkylamino, orguanidinium moiety.

1 In some embodiments, one or more of the cationic lipids present insuch a composition are chosen from XTC(2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane), MC3(((6Z,9Z,28Z,31 Z)-heptatriaconta-6,9,28,31-tetraen-19-yl4-(dimethylamino)butanoate), ALNY-100((3aR,5s,6aS)—N,N-dimethyl-2,2-di((9Z,12Z)-octadeca-9,12-dienyl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-5-amine)),NC98-5 (4,7,13-tris(3-oxo-3-(undecylamino)propyl)-N11,N16-diundecyl-4,7,10,13-tetraazahexadecane-1,16-diamide), DODAP(1,2-dioleyl-3-dimethylammonium propane), HGT4003 (WO 2012/170889, theteachings of which are incorporated herein by reference in theirentirety), ICE (WO 2011/068810, the teachings of which are incorporatedherein by reference in their entirety), HGT5000 (U.S. Provisional PatentApplication No. 61/617,468, the teachings of which are incorporatedherein by reference in their entirety) or HGT5001 (cis or trans)(Provisional Patent Application No. 61/617,468), aminoalcohol lipidoidssuch as those disclosed in WO2010/053572, DOTAP(1,2-dioleyl-3-trimethylammonium propane), DOTMA(1,2-di-O-octadecenyl-3-trimethylammonium propane), DLinDMA (Heyes, J.;Palmer, L.; Bremner, K.; MacLachlan, I. “Cationic lipid saturationinfluences intracellular delivery of encapsulated nucleic acids” J.Contr. Rel. 2005, 107, 276-287), DLin-KC2-DMA (Semple, S. C. et al.“Rational Design of Cationic Lipids for siRNA Delivery” Nature Biotech.2010, 28, 172-176), C12-200 (Love, K. T. et al. “Lipid-like materialsfor low-dose in vivo gene silencing” PNAS 2010, 107, 1864-1869).

In some embodiments, one or more of the cationic lipids present in sucha composition is a cationic lipid described in WO 2013063468 and in U.S.provisional application Ser. No. 61/894,299, entitled “LipidFormulations for Delivery of Messernger RNA” filed on Oct. 22, 2013,both of which are incorporated by reference herein. In some embodiments,a cationic lipid comprises a compound of formula I-c1-a:

or a pharmaceutically acceptable salt thereof, wherein:each R² independently is hydrogen or C₁₋₃ alkyl;each q independently is 2 to 6;each R′ independently is hydrogen or C₁₋₃ alkyl;and each R^(L) independently is C₈₋₁₂ alkyl.

In some embodiments, each R² independently is hydrogen, methyl or ethyl.In some embodiments, each R² independently is hydrogen or methyl. Insome embodiments, each R² is hydrogen.

In some embodiments, each q independently is 3 to 6. In someembodiments, each q independently is 3 to 5. In some embodiments, each qis 4.

In some embodiments, each R′ independently is hydrogen, methyl or ethyl.In some embodiments, each R′ independently is hydrogen or methyl. Insome embodiments, each R′ independently is hydrogen.

In some embodiments, each R^(L) independently is C₈₋₁₂ alkyl. In someembodiments, each R^(L) independently is n-C₈₋₁₂ alkyl. In someembodiments, each R^(L) independently is C₉₋₁₁ alkyl. In someembodiments, each R^(L) independently is n-C₉₋₁₁ alkyl. In someembodiments, each R^(L) independently is C₁₀ alkyl. In some embodiments,each R^(L) independently is n-C₁₀ alkyl.

In some embodiments, each R² independently is hydrogen or methyl; each qindependently is 3 to 5; each R′ independently is hydrogen or methyl;and each R^(L) independently is C₈₋₁₂ alkyl.

In some embodiments, each R² is hydrogen; each q independently is 3 to5; each R′ is hydrogen; and each R^(L) independently is C₈₋₁₂ alkyl.

In some embodiments, each R² is hydrogen; each q is 4; each R′ ishydrogen; and each R^(L) independently is C₈₋₁₂ alkyl.

In some embodiments, a cationic lipid comprises a compound of formulaI-g:

or a pharmaceutically acceptable salt thereof, wherein each R^(L)independently is C₈₋₁₂ alkyl. In some embodiments, each R^(L)independently is n-C₈₋₁₂ alkyl. In some embodiments, each R^(L)independently is C₉₋₁₁ alkyl. In some embodiments, each R^(L)independently is n-C₉₋₁₁ alkyl. In some embodiments, each R^(L)independently is C₁₀ alkyl. In some embodiments, each R^(L) is n-C₁₀alkyl.

In particular embodiments, provided compositions include a cationiclipid cKK-E12, or(3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione).Structure of cKK-E12 is shown below:

In some embodiments, a suitable delivery vehicle contains one or morenon-cationic lipids, In some embodiments, a non-cationic lipid is aneutral lipid, i.e., a lipid that does not carry a net charge in theconditions under which the composition is formulated and/oradministered. Such exemplary non-cationic or neutral lipids can bechosen from DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), DPPC(1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DOPE(1,2-dioleyl-sn-glycero-3-phosphoethanolamine), DPPE(1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine), DMPE(1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine), DOPG(1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol)), and cholesterol.

The use of cholesterol-based cationic lipids is also contemplated by thepresent invention. Such cholesterol-based cationic lipids can be used,either alone or in combination with other cationic or non-cationiclipids. Suitable cholesterol-based cationic lipids include, for example,DC-Choi (N,N-dimethyl-N-ethylcarboxamidocholesterol),1,4-bis(3-N-oleylamino-propyl)piperazine (Gao, et al. Biochem. Biophys.Res. Comm. 179, 280 (1991); Wolf et al. BioTechniques 23, 139 (1997);U.S. Pat. No. 5,744,335), or ICE.

In other embodiments, suitable lipid nanoparticles comprising one ormore cleavable lipids, such as, for example, one or more cationic lipidsor compounds that comprise a cleavable disulfide (S—S) functional group(e.g., HGT4001, HGT4002, HGT4003, HGT4004 and HGT4005), as furtherdescribed in U.S. Provisional Application No. 61/494,745, the entireteachings of which are incorporated herein by reference in theirentirety.

In addition, several reagents are commercially available to enhancetransfection efficacy. Suitable examples include LIPOFECTIN (DOTMA:DOPE)(Invitrogen, Carlsbad, Calif.), LIPOFECTA INE (DOSPA:DOPE) (Invitrogen),LIPOFECTAMINE2000. (Invitrogen), FUGENE, TRANSFECTAM (DOGS), andEFFECTENE.

In some embodiments, the cationic lipid may comprise a molar ratio ofabout 1% to about 90%, about 2% to about 70%, about 5% to about 50%,about 10% to about 40% of the total lipid present in the transfervehicle, or preferably about 20% to about 70% of the total lipid presentin the transfer vehicle.

The use of polyethylene glycol (PEG)-modified phospholipids andderivatized lipids such as derivatized cerarmides (PEG-CER), includingN-Octanoyl-Sphingosine-1-[Succinyl(Methoxy Polyethylene Glycol)-2000](C8 PEG-2000 ceramide) is also contemplated by the present invention,either alone or preferably in combination with other lipids togetherwhich comprise the transfer vehicle (e.g., a lipid nanoparticle).Contemplated PEG-modified lipids include, but is not limited to, apolyethylene glycol chain of up to 5 kDa in length covalently attachedto a lipid with alkyl chain(s) of C6-C20 length. The addition of suchcomponents may prevent complex aggregation and may also provide a meansfor increasing circulation lifetime and increasing the delivery of thelipid-nucleic acid composition to the target cell, (Klibanov et al.(1990) FEBS Letters, 268 (1): 235-237), or they may be selected torapidly exchange out of the formulation in vivo (see U.S. Pat. No.5,885,613).

Particularly useful exchangeable lipids are PEG-ceramides having shorteracyl chains (e.g., C14 or C18). The PEG-modified phospholipid andderivitized lipids of the present invention may comprise a molar ratiofrom about 0% to about 20%, about 0.5% to about 20%, about 1% to about15%, about 4% to about 10%, or about 2% of the total lipid present inthe liposomal transfer vehicle.

The present invention also contemplates the use of non-cationic lipids.As used herein, the phrase “non-cationic lipid” refers to any neutral,zwitterionic or anionic lipid. As used herein, the phrase “anioniclipid” refers to any of a number of lipid species that carry a netnegative charge at a selected H, such as physiological pH. Non-cationiclipids include, but are not limited to, distearoylphosphatidylcholine(DSPC), dioleoylphosphatidylcholine (DOPC),dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol(DOPG), dipalmitoylphosphatidylglyceml (DPPG),dioleoylphosphatidylethanolamine (DOPE),palmitoyloleoylphosphatidylcholine (POPC),palmitoyloleoyl-phosphatidylethanolamine (POPE),dioleoyl-phosphatidylethanolamine4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoylphosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE),distearoyl-phosphatidyl-ethanolamine (DSPE), 16-O-monomethyl PE,16-O-dimethyl PE, 18-1-trans PE,1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), cholesterol, or amixture thereof. Such non-cationic lipids may be used alone, but arepreferably used in combination with other excipients, for example,cationic lipids. When used in combination with a cationic lipid, thenon-cationic lipid may comprise a molar ratio of 5% to about 90%, orpreferably about 10% to about 70% of the total lipid present in thetransfer vehicle.

In particular embodiments, a suitable transfer vehicle (e.g., a lipidnanoparticle) is prepared by combining multiple lipid and/or polymercomponents. For example, a transfer vehicle may be prepared usingC12-200, DOPE, chol, DMG-PEG2K at a molar ratio of 40:30:25:5, or DODAP,DOPE, cholesterol, DMG-PEG2K at a molar ratio of 18:56:20:6, or HGT5000,DOPE, chol, DMG-PEG2K at a molar ratio of 40:20:35:5, or HGT5001, DOPE,chol, DMG-PEG2K at a molar ratio of 40:20:35:5. The selection ofcationic lipids, non-cationic lipids and/or PEG-modified lipids whichcomprise the lipid nanoparticle, as well as the relative molar ratio ofsuch lipids to each other, is based upon the characteristics of theselected lipid(s), the nature of the intended target cells, thecharacteristics of the mRNA to be delivered. Additional considerationsinclude, for example, the saturation of the alkyl chain, as well as thesize, charge, pH, pKa, fusogenicity and toxicity of the selectedlipid(s). Thus the molar ratios may be adjusted accordingly. Forexample, in embodiments, the percentage of cationic lipid in the lipidnanoparticle may be greater than 10%, greater than 20%, greater than30%, greater than 40%, greater than 50%, greater than 60%, or greaterthan 70%. The percentage of non-cationic lipid in the lipid nanoparticlemay be greater than 5%, greater than 10%, greater than 20%, greater than30%, or greater than 40%. The percentage of cholesterol in the lipidnanoparticle may be greater than 10%, greater than 20%, greater than30%, or greater than 40%. The percentage of PEG-modified lipid in thelipid nanoparticle may be greater than 1%, greater than 2%, greater than5%, greater than 10%, or greater than 20%.

In certain embodiments, suitable lipid nanoparticles of the inventioncomprise at least one of the following cationic lipids: C12-200,DLin-KC2-DMA, DODAP, HGT4003, ICE, HGT5000, or HGT5001. In someembodiments, suitable transfer vehicle comprises cholesterol and/or aPEG-modified lipid. In some embodiments, suitable transfer vehiclescomprises DMG-PEG2K. In some embodiments, suitable transfer vehiclecomprises one of the following lipid combinations: C12-200, DOPE,cholesterol, DMG-PEG2K; DODAP, DOPE, cholesterol, DMG-PEG2K; HGT5000,DOPE, cholesterol, DMG-PEG2K; HGT5001, DOPE, cholesterol, DMG-PEG2K;XTC, DSPC, cholesterol, PEG-DMG; MC3, DSPC, cholesterol, PEG-DMG; andALNY-100, DSPC, cholesterol, PEG-DSG.

The liposomal transfer vehicles for use in the compositions of theinvention can be prepared by various techniques which are presentlyknown in the art. Multilamellar vesicles (MLV) may be preparedconventional techniques, for example, by depositing a selected lipid onthe inside wall of a suitable container or vessel by dissolving thelipid in an appropriate solvent, and then evaporating the solvent toleave a thin film on the inside of the vessel or by spray drying. Anaqueous phase may then added to the vessel with a vortexing motion whichresults in the formation of MLVs. Uni-lamellar vesicles (ULV) can thenbe formed by homogenization, sonication or extrusion of themulti-lamellar vesicles. In addition, unilamellar vesicles can be formedby detergent removal techniques.

In certain embodiments of this invention, the compositions of thepresent invention comprise a transfer vehicle wherein the mRNA isassociated on both the surface of the transfer vehicle and encapsulatedwithin the same transfer vehicle. For example, during preparation of thecompositions of the present invention, cationic liposomal transfervehicles may associate with the mRNA through electrostatic interactions.For example, during preparation of the compositions of the presentinvention, cationic liposomal transfer vehicles may associate with themRNA through electrostatic interactions.

Suitable liposomal delivery vehicles according to the present inventionmay be made in various sizes. Selection of an appropriate size may takeinto consideration the site of the target cell or tissue and to someextent the application for which the liposome is being made. In someembodiments, an appropriate size of liposomal delivery vehicles isselected to facilitate systemic distribution of antibody encoded by themRNA. In some embodiments, it may be desirable to limit transfection ofthe mRNA to certain cells or tissues. For example, to target hepatocytesa liposomal transfer vehicle may be sized such that its dimensions aresmaller than the fenestrations of the endothelial layer lining hepaticsinusoids in the liver; accordingly the liposomal transfer vehicle canreadily penetrate such endothelial fenestrations to reach the targethepatocytes. Alternatively, a liposomal transfer vehicle may be sizedsuch that the dimensions of the liposome are of a sufficient diameter tolimit or expressly avoid distribution into certain cells or tissues. Forexample, a liposomal transfer vehicle may be sized such that itsdimensions are larger than the fenestrations of the endothelial layerlining hepatic sinusoids to thereby limit distribution of the liposomaltransfer vehicle to hepatocytes.

In some embodiments, a suitable liposomal delivery vehicle has a size nogreater than about 250 nm (e.g., no greater than about 225 nm, 200 nm,175 nm, 150 nm, 125 nm, 100 nm, 75 nm, or 50 nm). In some embodiments, asuitable liposomal delivery vehicle has a size ranging from about 250-10nm (e.g., ranging from about 225-10 nm, 200-10 nm, 175-10 nm, 150-10 nm,125-10 nm, 100-10 nm, 75-10 nm, or 50-10 nm). In some embodiments, asuitable liposomal delivery vehicle has a size ranging from about250-100 nm (e.g., ranging from about 225-100 nm, 200-100 nm, 175-100 nm,150-100 nm). In some embodiments, a suitable liposomal delivery vehiclehas a size ranging from about 100-10 nm (e.g., ranging from about 90-10nm, 80-10 nm, 70-10 nm, 60-10 nm, or 50-10 nm).

A variety of alternative methods known in the art are available forsizing of a population of liposomal transfer vehicles. One such sizingmethod is described in U.S. Pat. No. 4,737,323, incorporated herein byreference. Sonicating a liposome suspension either by bath or probesonication produces a progressive size reduction down to small ULV lessthan about 0.05 microns in diameter. Homogenization is another methodthat relies on shearing energy to fragment large liposomes into smallerones. In a typical homogenization procedure, MLV are recirculatedthrough a standard emulsion homogenizer until selected liposome sizes,typically between about 0.1 and 0.5 microns, are observed. The size ofthe liposomal vesicles may be determined by quasi-electric lightscattering (QELS) as described in Bloomfield, Ann. Rev. Biophys.Bioeng., 10:421-150 (1981), incorporated herein by reference. Averageliposome diameter may be reduced by sonication of formed liposomes.Intermittent sonication cycles may be alternated with QELS assessment toguide efficient liposome synthesis.

Expression of RNA Coded Antibodies In Vivo

According to the present invention, antibody encoding mRNAs (e.g., heavychain and light chain encoding mRNAs) described herein may be delivered,with or without delivery vehicles, to a subject in need of delivery suchthat a fully assembled desired antibody is expressed in vivo.

In some embodiments, a desired antibody encoded by mRNAs is expressedsystemically in the subject. This can be achieved by secreting fullyassembled antibodies from a cell or tissue in which the antibody isinitially expressed into the circulation system of the subject. Forexample, compositions of the invention containing antibody encodingmRNAs and lipososmal vehicles distribute into the cells of the liver tofacilitate the delivery and the subsequent expression of the mRNAcomprised therein by the cells of the liver (e.g., hepatocytes). Thetargeted hepatocytes may function as a biological “reservoir” or “depot”capable of producing, and excreting a fully assembled desired antibody,resulting in systemic distribution of the antibody. In otherembodiments, cells other than hepatocytes (e.g., lung, spleen, heart,ocular, or cells of the central nervous system) can serve as a depotlocation for protein production. Typically, sustained production andsecretion of fully assembled antibodies from the reservoir or depotcells results in effective systemic distribution.

In some embodiments, systemic expression of a desired antibody encodedmRNAs in the patient serum (i.e., blood) is detectable for more than 1hour, more than 4 hours, more than 6 hours, more than 12 hours, morethan 18 hours, more than 24 hours, more than 30 hours, more than 36hours, more than 42 hours, more than 48 hours, more than 54 hours, morethan 60 hours, more than 66 hours, more than 72 hours, more than 96hours, more than 120 hours, more than 144 hours, more than 168 hours,more than 2 weeks, more than 3 weeks, more than 1 month or more than 2months after administration. In some embodiments, the serumconcentration of the antibody encoded by mRNAs reaches a peak levelabout 6 hours, 12 hours, 18 hours, 24 hours, 30 hours, 36 hours, 42hours, 48 hours, 54 hours, 60 hours, 66 hours, 72 hours, 78 hours, 84hours, 90 hours, or 96 hours after administration. In some embodiments,sustained circulation of the desired antibody encoded by mRNAs areobserved. For example, the systemic expression of the antibody encodedby mRNAs in the patient serum (i.e., blood) may be detected for morethan 1 day, 2 days, 3 days, 4 days, 5 days, 1 week, 2 weeks, 3 weeks, 1month, 2 months or more after administration.

In some embodiments, mRNAs encoding heavy chain and light chain of anantibody may be delivered to target cells or tissues for intracellularexpression or local distribution of the antibody. Typically, localdistribution results when a fully assembled antibody is produced andsecreted from a target cell to the surrounding extracellular fluidwithout entering the circulation system, such as blood stream. As usedherein, the term “target cell” or “target tissue” refers to a cell ortissue to which antibody encoding mRNA(s) is to be directed or targeted.For example, where it is desired to deliver an mRNA to a hepatocyte, thehepatocyte represents the target cell. Antibody encoding mRNAs (e.g.,heavy chain and light chain encoding mRNAs) described herein may bedelivered to a variety of target cells or tissues including, but notlimited to, hepatocytes, epithelial cells, hematopoietic cells,epithelial cells, endothelial cells, lung cells, bone cells, stem cells,mesenchymal cells, neural cells (e.g., meninges, astrocytes, motorneurons, cells of the dorsal root ganglia and anterior horn motorneurons), photoreceptor cells (e.g., rods and cones), retinal pigmentedepithelial cells, secretory cells, cardiac cells, adipocytes, vascularsmooth muscle cells, cardiomyocytes, skeletal muscle cells, beta cells,pituitary cells, synovial lining cells, ovarian cells, testicular cells,fibroblasts, B cells, T cells, reticulocytes, leukocytes, granulocytesand tumor cells.

Delivery of mRNAs to target cells and tissues may be accomplished byboth passive and active targeting means. The phenomenon of passivetargeting exploits the natural distributions patterns of a transfervehicle in vivo without relying upon the use of additional excipients ormeans to enhance recognition of the transfer vehicle by target cells.For example, transfer vehicles which are subject to phagocytosis by thecells of the reticulo-endothelial system are likely to accumulate in theliver or spleen, and accordingly may provide means to passively directthe delivery of the compositions to such target cells.

Alternatively, delivery of mRNAs to target cells and tissues may beaccomplished by active targeting, which involves the use of additionalexcipients, referred to herein as “targeting ligands” that may be bound(either covalently or non-covalently) to the transfer vehicle toencourage localization of such transfer vehicle at certain target cellsor target tissues. For example, targeting may be mediated by theinclusion of one or more endogenous targeting ligands (e.g.,apolipoprotein E) in or on the transfer vehicle to encouragedistribution to the target cells or tissues. Recognition of thetargeting ligand by the target tissues actively facilitates tissuedistribution and cellular uptake of the transfer vehicle and/or itscontents in the target cells and tissues (e.g., the inclusion of anapolipoprotein-E targeting ligand in or on the transfer vehicleencourages recognition and binding of the transfer vehicle to endogenouslow density lipoprotein receptors expressed by hepatocytes). As providedherein, the composition can comprise a ligand capable of enhancingaffinity of the composition to the target cell. Targeting ligands may belinked to the outer bilayer of the lipid particle during formulation orpost-formulation. These methods are well known in the art. In addition,some lipid particle formulations may employ fusogenic polymers such asPEAA, Hemagglutinin, other lipopeptides (see U.S. patent applicationSer. Nos. 08/835,281, and 60/083,294, which are incorporated herein byreference) and other features useful for in vivo and/or intracellulardelivery. In other some embodiments, the compositions of the presentinvention demonstrate improved transfection efficacies, and/ordemonstrate enhanced selectivity towards target cells or tissues ofinterest. Contemplated therefore are compositions which comprise one ormore ligands (e.g., peptides, aptamers, oligonucleotides, a vitamin orother molecules) that are capable of enhancing the affinity of thecompositions and their nucleic acid contents for the target cells ortissues. Suitable ligands may optionally be bound or linked to thesurface of the transfer vehicle. In some embodiments, the targetingligand may span the surface of a transfer vehicle or be encapsulatedwithin the transfer vehicle. Suitable ligands and are selected basedupon their physical, chemical or biological properties (e.g., selectiveaffinity and/or recognition of target cell surface markers or features)Cell-specific target sites and their corresponding targeting ligand canvary widely. Suitable targeting ligands are selected such that theunique characteristics of a target cell are exploited, thus allowing thecomposition to discriminate between target and non-target cells. Forexample, compositions of the invention may include surface markers(e.g., apolipoprotein-B or apolipoprotein-E) that selectively enhancerecognition of, or affinity to hepatocytes (e.g., by receptor-mediatedrecognition of and binding to such surface markers). Additionally, theuse of galactose as a targeting ligand would be expected to direct thecompositions of the present invention to parenchymal hepatocytes, oralternatively the use of mannose containing sugar residues as atargeting ligand would be expected to direct the compositions of thepresent invention to liver endothelial cells (e.g., mannose containingsugar residues that may bind preferentially to the asialoglycoproteinreceptor or mannose receptor present in hepatocytes). (See Hillery A M,et al. “Drug Delivery and Targeting: For Pharmacists and PharmaceuticalScientists” (2002) Taylor & Francis, Inc.) The presentation of suchtargeting ligands that have been conjugated to moieties present in thetransfer vehicle (e.g., a lipid nanoparticle) therefore facilitaterecognition and uptake of the compositions of the present invention intarget cells and tissues. Examples of suitable targeting ligands includeone or more peptides, proteins, aptamers, vitamins and oligonucleotides.

As used herein, the term “subject” refers to any animal (e.g., amammal), including, but not limited to, humans, non-human primates,rodents, and the like, to which the mRNAs and compositions of thepresent invention are administered. Typically, the terms “subject” and“patient” are used interchangeably herein in reference to a humansubject.

Pharmaceutical Composition and Administration

To facilitate expression of antibodies in vivo, antibody encoding mRNAs(e.g., heavy chain and light chain encoding mRNAs) and delivery vehiclescan be formulated in combination with one or more additional nucleicacids, carriers, targeting ligands or stabilizing reagents, or inpharmacological compositions where it is mixed with suitable excipients.Techniques for formulation and administration of drugs may be found in“Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, Pa.,latest edition.

Antibody encoding mRNAs and compositions containing the same may beadministered and dosed in accordance with current medical practice,taking into account the clinical condition of the subject, the site andmethod of administration, the scheduling of administration, thesubject's age, sex, body weight and other factors relevant to cliniciansof ordinary skill in the art. The “effective amount” for the purposesherein may be determined by such relevant considerations as are known tothose of ordinary skill in experimental clinical research,pharmacological, clinical and medical arts. In some embodiments, theamount administered is effective to achieve at least some stabilization,improvement or elimination of symptoms and other indicators as areselected as appropriate measures of disease progress, regression orimprovement by those of skill in the art. For example, a suitable amountand dosing regimen is one that causes at least transient antibodyproduction.

Suitable routes of administration include, for example, oral, rectal,vaginal, transmucosal, pulmonary including intratracheal or inhaled, orintestinal administration; parenteral delivery, including intramuscular,subcutaneous, intramedullary injections, as well as intrathecal, directintraventricular, intravenous, intraperitoneal, intranasal, orintraocular injections.

Alternately, mRNAs and compositions of the invention may be administeredin a local rather than systemic manner, for example, via injection ofthe pharmaceutical composition directly into a targeted tissue,preferably in a sustained release formulation. Local delivery can beaffected in various ways, depending on the tissue to be targeted. Forexample, aerosols containing compositions of the present invention canbe inhaled (for nasal, tracheal, or bronchial delivery); compositions ofthe present invention can be injected into the site of injury, diseasemanifestation, or pain, for example; compositions can be provided inlozenges for oral, tracheal, or esophageal application; can be suppliedin liquid, tablet or capsule form for administration to the stomach orintestines, can be supplied in suppository form for rectal or vaginalapplication; or can even be delivered to the eye by use of creams,drops, or even injection. Formulations containing compositions of thepresent invention complexed with therapeutic molecules or ligands caneven be surgically administered, for example in association with apolymer or other structure or substance that can allow the compositionsto diffuse from the site of implantation to surrounding cells.Alternatively, they can be applied surgically without the use ofpolymers or supports.

In one embodiment, the compositions of the invention are formulated suchthat they are suitable for extended-release of the mRNA containedtherein. Such extended-release compositions may be convenientlyadministered to a subject at extended dosing intervals. For example, inone embodiment, the compositions of the present invention areadministered to a subject twice day, daily or every other day. In apreferred embodiment, the compositions of the present invention areadministered to a subject twice a week, once a week, every ten days,every two weeks, every three weeks, or more preferably every four weeks,once a month, every six weeks, every eight weeks, every other month,every three months, every four months, every six months, every eightmonths, every nine months or annually. Also contemplated arecompositions and liposomal vehicles which are formulated for depotadministration (e.g., intramuscularly, subcutaneously, intravitreally)to either deliver or release a mRNA over extended periods of time.Preferably, the extended-release means employed are combined withmodifications made to the mRNA to enhance stability.

Also contemplated herein are lyophilized pharmaceutical compositionscomprising one or more of the liposomal nanoparticles disclosed hereinand related methods for the use of such lyophilized compositions asdisclosed for example, in U.S. Provisional Application No. 61/494,882,filed Jun. 8, 2011, the teachings of which are incorporated herein byreference in their entirety. For example, lyophilized pharmaceuticalcompositions according to the invention may be reconstituted prior toadministration or can be reconstituted in vivo. For example, alyophilized pharmaceutical composition can be formulated in anappropriate dosage form (e.g., an intradermal dosage form such as adisk, rod or membrane) and administered such that the dosage form isrehydrated over time in vivo by the individual's bodily fluids.

Expression of RNA Coded Antibodies In Vitro

In some embodiments, antibody encoding mRNAs (e.g., heavy chain andlight chain encoding mRNAs) may be used to produce antibodies in vitro.For example, cells may be transfected by antibody encoding mRNAs (e.g.,heavy chain and light chain encoding mRNAs) and cultured under cellculture conditions that allow the production of the antibody by thecells. In some embodiments, the antibody is expressed intracellularly.In other embodiments, the antibody is secreted by the cells such thatthe antibody may be harvested from the supernatant.

In some embodiments, mammalian cells are used in accordance with thepresent invention. Non-limiting examples of mammalian cells includeBALB/c mouse myeloma line (NSO/1, ECACC No: 85110503); humanretinoblasts (PER.C6, CruCell, Leiden, The Netherlands); monkey kidneyCV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonickidney line (HEK293 or 293 cells subcloned for growth in suspensionculture, Graham et al., J. Gen Virol., 36:59, 1977); human fibrosarcomacell line (e.g., HT1080); baby hamster kidney cells (BHK21, ATCC CCL10); Chinese hamster ovary cells +/−DHFR (CHO, Urlaub and Chasin, Proc.Natl. Acad. Sci. USA, 77:4216, 1980); mouse sertoli cells (TM4, Mather,Biol. Reprod., 23:243-251, 1980); monkey kidney cells (CV1 ATCC CCL 70);African green monkey kidney cells (VERO-76, ATCC CRL-1 587); humancervical carcinoma cells (HeLa, ATCC CCL 2); canine kidney cells (MDCK,ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); humanlung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065);mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al.,Annals N.Y. Acad. Sci., 383:44-68, 1982); MRC 5 cells; FS4 cells; and ahuman hepatoma line (Hep G2).

Standard cell culture media and conditions may be used to cultivatetransfected cells and produce desired antibodies encoded by mRNAs.

EXAMPLES Example 1. Production of mRNA

Heavy chain anti-chemokine (C—C motif) ligand 2 (HC-αCCL2, SEQ ID NO: 1)and light chain anti-CCL2 (LC-αCCL2, SEQ ID NO: 2) were synthesized byin vitro transcription from a plasmid DNA template encoding the gene,which was followed by the addition of a 5′ cap structure (Cap1)according to known methods (see Fechter, P.; Brownlee, G. G.“Recognition of mRNA cap structures by viral and cellular proteins” J.Gen. Virology 2005, 86, 1239-1249) and a 3′ poly(A) tail ofapproximately 200 nucleotides in length as determined by gelelectrophoresis. The sequences for HC-αCCL2 and LC-αCCL2 were as shownbelow, and 5′ and 3′ untranslated regions present in each mRNA productare represented as X and Y, respectively, and defined below:

Heavy chain anti-CCL2 (HC-αCCL2) mRNA: X₁AUGGAAUUCGGCCUGAGCUGGCUGUUCCUGGUGGCCAUCCUGAAGGGCGUGCAGUGCCAGGUCCAGCUGGUGCAGUCUGGCGCCGAAGUGAAGAAACCCGGCUCCUCCGUGAAGGUGUCCUGCAAGGCCUCCGGCGGCACCUUCUCCAGCUACGGCAUCUCCUGGGUCCGACAGGCCCCAGGCCAGGGCCUGGAAUGGAUGGGCGGCAUCAUCCCCAUCUUCGGCACCGCCAACUACGCCCAGAAAUUCCAGGGCAGAGUGACCAUCACCGCCGACGAGUCCACCUCCACCGCCUACAUGGAACUGUCCUCCCUGCGGAGCGAGGACACCGCCGUGUACUACUGCGCCAGAUACGACGGCAUCUACGGCGAGCUGGACUUCUGGGGCCAGGGCACCCUGGUCACCGUGUCCUCUGCCAAGACCACCCCCCCCUCCGUGUACCCUCUGGCCCCUGGCUCUGCCGCCCAGACCAACUCUAUGGUCACCCUGGGCUGCCUGGUCAAGGGCUACUUCCCCGAGCCCGUGACCGUGACCUGGAACUCCGGCUCCCUGUCCUCCGGCGUGCACACCUUCCCUGCCGUGCUGCAGUCCGACCUCUACACCCUGUCCAGCAGCGUGACCGUGCCCUCCUCCACCUGGCCCUCCGAGACAGUGACCUGCAACGUGGCCCACCCCGCCUCCAGCACCAAGGUGGACAAGAAAAUCGUGCCCCGGGACUGCGGCUGCAAGCCCUGCAUCUGUACCGUGCCCGAGGUGUCCUCCGUGUUCAUCUUCCCACCCAAGCCCAAGGACGUGCUGACCAUCACACUGACCCCCAAAGUGACCUGCGUGGUGGUGGACAUCUCCAAGGACGACCCCGAGGUGCAGUUCAGUUGGUUCGUGGACGACGUGGAAGUGCACACCGCUCAGACCCAGCCCAGAGAGGAACAGUUCAACUCCACCUUCAGAUCCGUGUCCGAGCUGCCCAUCAUGCACCAGGACUGGCUGAACGGCAAAGAAUUCAAGUGCAGAGUGAACUCCGCCGCCUUCCCAGCCCCCAUCGAAAAGACCAUCUCCAAGACCAAGGGCAGACCCAAGGCCCCCCAGGUCUACACCAUCCCCCCACCCAAAGAACAGAUGGCCAAGGACAAGGUGUCCCUGACCUGCAUGAUCACCGAUUUCUUCCCAGAGGACAUCACCGUGGAAUGGCAGUGGAACGGCCAGCCCGCCGAGAACUACAAGAACACCCAGCCCAUCAUGGACACCGACGGCUCCUACUUCGUGUACUCCAAGCUGAACGUGCAGAAGUCCAACUGGGAGGCCGGCAACACCUUCACCUGUAGCGUGCUGCACGAGGGCCUGCACAACCACCACACCGAGAAGUCCCUGUCCCACU CCCCCGGCAAGUGAY ₁Light chain anti-CCL2 (LC-αCCL2) mRNA: X₁AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUGGCUGCCUGAUACCACCGGCGAAAUCGUGCUGACCCAGUCCCCCGCCACCCUGUCUCUGAGCCCUGGCGAGAGAGCCACCCUGAGCUGCAGAGCCUCCCAGUCCGUGUCCGACGCCUACCUGGCCUGGUAUCAGCAGAAGCCCGGCCAGGCCCCUCGGCUGCUGAUCUACGACGCCUCCUCUAGAGCCACCGGCGUGCCCGCCAGAUUCUCCGGCUCUGGCUCUGGCACCGACUUCACCCUGACCAUCUCCAGCCUGGAACCCGAGGACUUCGCCGUGUACUACUGCCACCAGUACAUCCAGCUGCACAGCUUCACCUUCGGCCAGGGCACCAAGGUGGAAAUCAAGGCCGAUGCCGCCCCUACCGUGUCCAUCUUCCCACCCUCCAGCGAGCAGCUGACCUCUGGCGGCGCUUCCGUCGUGUGCUUCCUGAACAACUUCUACCCCAAGGACAUCAACGUGAAGUGGAAGAUCGACGGCUCCGAGCGGCAGAACGGCGUGCUGAACUCCUGGACCGACCAGGACUCCAAGGACAGCACCUACUCCAUGUCCUCCACCCUGACCCUGACCAAGGACGAGUACGAGCGGCACAACUCCUAUACCUGCGAGGCCACCCACAAGACCUCCACCUCCCCCAUCGUGAAGUCCUUCAACCGGAACGAGUGCUGAY ₁5′ and 3′ UTR Sequences: X₁ =GGACAGAUCGCCUGGAGACGCCAUCCACGCUGUUUUGACCUCCAUAGAAGACACCGGGACCGAUCCAGCCUCCGCGGCCGGGAACGGUGCAUUGGAACGCGGAUUCCCCGUGCCAAGAGUGACUCACCGUCCUUGACACG Y₁ =CGGGUGGCAUCCCUGUGACCCCUCCCCAGUGCCUCUCCUGGCCCUGGAAGUUGCCACUCCAGUGCCCACCAGCCUUGUCCUAAUAAAAUUAAGUUGCAUCAA GCU

Example 2. In Vitro mRNA Transfection Materials and Conditions

A. Exemplary Lipid Materials

The lipid formulations used for transfection in the examples hereinconsisted of one or more lipids or a multi-component lipid mixture ofvarying ratios employing one or more cationic lipids, helper lipids andPEGylated lipids designed to encapsulate various nucleic acid-basedmaterials. Cationic lipids can include (but not exclusively) DOTAP(1,2-dioleyl-3-trimethylammonium propane), DODAP(1,2-dioleyl-3-dimethylammonium propane), DOTMA(1,2-di-O-octadecenyl-3-trimethylammonium propane), DLinDMA (see Heyes,J.; Palmer, L.; Bremner, K.; MacLachlan, I. “Cationic lipid saturationinfluences intracellular delivery of encapsulated nucleic acids” J.Contr. Rel. 2005, 107, 276-287), DLin-KC2-DMA (see Semple, S. C. et al.“Rational Design of Cationic Lipids for siRNA Delivery” Nature Biotech.2010, 28, 172-176), C12-200 (Love, K. T. et al. “Lipid-like materialsfor low-dose in vivo gene silencing” PNAS 2010, 107, 1864-1869),HGT4003, ICE, dialkylamino-based, imidazole-based, guanidinium-based,etc. Helper lipids can include (but not exclusively) DSPC(1,2-distearoyl-sn-glycero-3-phosphocholine), DPPC(1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DOPE(1,2-dioleyl-sn-glycero-3-phosphoethanolamine), DPPE(1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine), DMPE(1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine), DOPG(2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol)), cholesterol, etc.The PEGylated lipids can include (but not exclusively) a poly(ethylene)glycol chain of up to 5 kDa in length covalently attached to a lipidwith alkyl chain(s) of C₆-C₂₀ length.

B. Experimental Formulations

In these experiments, aliquots of 50 mg/mL ethanolic solutions ofC12-200, DOPE, cholesterol and DMG-PEG2K were mixed and diluted withethanol to 3 mL final volume. Separately, an aqueous buffered solution(10 mM citrate/150 mM NaCl, pH 4.5) of HC-αCCL2 mRNA and LC-αCCL2 mRNA(1:1 wt:wt) mRNA was prepared by addition of 500 microgram of eachconstruct from a 1 mg/mL stock. The lipid solution was injected rapidlyinto the aqueous mRNA solution and shaken to yield a final suspension in20% ethanol. The resulting nanoparticle suspension was filtered,diafiltrated with 1×PBS (pH 7.4), concentrated and stored at 2-8° C.Final concentration=1.35 mg/mL αCCL2 mRNA (encapsulated). Z_(ave)=89.2nm (Dv₍₅₀₎=64.0 nm; Dv₍₉₀₎=115 nm).

Example 3. Detection of Antibody after In Vitro mRNA Transfection

A. Via ELISA

In this example, F96 MaxiSorp Nunc-Immuno Plates were coated with 100 μlof 1 μg/ml of goat anti mouse IgG1 (Invitrogen A 10538) in sodiumcarbonate buffer, pH 9.6 and incubated 1 hr at 37° C. After washing 3×with wash buffer (1×PBS, 0.05% Tween 20), the wells were blocked with320 μl blocking buffer (1×PBS, 0.05% Tween 20, 2% BSA) for 1 hr at 37°C. Serial dilutions of monoclonal IgG standards were prepared inblocking buffer in the range from 250-0 ng/ml. Serial dilutions of thesamples were prepared in blocking buffer to be in the range of thestandard curve (1:100 to 1:10,000). Both samples and standards wereincubated 1 hr at 37° C. After washing 3× with wash buffer, goat antimouse IgG Fc HRP conjugated secondary antibody (Pierce 31439) was usedat 1:40,000 dilution and incubated at 37° C. for 1 hr. After washing 3×with wash buffer TMB EIA substrate reagent was prepared according tomanufactures instructions. After 15 min incubation at 37° C., thereaction was stopped by adding 2N H₂SO₄ and the plate read at 450 nm.

B. Via Western Blot

In this example, conditioned medium from transfected 293T cells orelectroporated HCL2 cells were fractionated by SDS-PAGE and transferredto a polyvinylidene difluoride membrane using a transfer apparatusaccording to the manufacturer's instructions (Invitrogen). Afterincubation with 5% non-fat dry milk in TBST (10 mM Tris, pH 8.0, 150 mMNaCl, 0.5% Tween 20) for 1 hr, the membrane was washed three times withPBST and incubated with goat anti mouse IgG (Invitrogen A10538) for 1 hrat RT. Membranes were washed three times in PBST and incubated with1:5000 dilution of horseradish peroxidase conjugated anti-mousesecondary antibody (Promega W4021) for 1 hr at RT. Blots were washed inPBST three more times and developed with the ECL system (AmershamBioscience) according to manufacturer's instructions.

Example 4. In Vitro Analysis of αCCL2 Antibody Produced fromTransfection of HC-αCCL2 and LC-αCCL2

Both HC-αCCL2 and LC-αCCL2 mRNA were produced as described above inExample 1. Subsequently, in accordance with Example 2A and B, HC-αCCL2and LC-αCCL2 mRNA was transfected into either HCL1 (i.e., human cellline 1) cells or HCL2 cells in various rations (wt:wt) according toknown methods.

The results of these studies in HCL1 cells and HCL2 cells aredemonstrated in FIGS. 1 and 2, respectively. Various mixtures of α-CCL2(chemokine (C—C motif) ligand 2) heavy chain and light chain mRNAconstructs were mixed (wt:wt) and transfected into either HCL1 cells(FIG. 1) or HCL2 cells (FIG. 2). Cell supernatants were harvested atselect time points post-transfection and analyzed for the presence ofanti-mouse IgG using ELISA-based methods as described above in Example3A.

As shown in FIGS. 1 and 2, varying the ratio of heavy chain to lightchain (wt:wt) produced a significant difference in protein production asdetermined via ELISA. While a 1:1 (wt:wt) mixture of heavy chain:lightchain α-CCL2 mRNA provided strong signal in HCL2 cells, a 4:1 (wt:wt)ratio provided higher protein production in HCL1 cells. While there weredifferences among the varying ratios, strong protein production wasobserved for all ratios tested. Further, in both cases, 48 hrpost-transfection (Day 2, or D2) gave the strongest signal of desiredprotein in this example.

To further confirm the presence of the exogenous mRNA-derived antibody,immunoblot (Western) techniques were employed for additionalcharacterization (see FIG. 3) of HCL1-derived samples. Heavy chain andlight chain fragments were successfully detected in the supernatant ofmRNA transfected HCL1 cells using western blot methods as described inexample 3B. Samples were analyzed 24 and 48 hours post-transfection ofvarious mixtures of α-CCL2 heavy chain and light chain mRNA constructs(wt:wt). Band intensities observed were reflective of the mRNA ratiosemployed in each example.

Example 5. In Vivo Analysis of αCCL2 Antibody Produced fromIntravenously Administered mRNA-Loaded Nanoparticles

In this example, production of fully processed antibody was accomplishedin vivo via delivery of exogenous messenger RNA, specifically, α-CCL2heavy chain and light chain mRNA constructs (HC-αCCL2:LC-αCCL2 mRNA, 1:1(wt:wt)) were encapsulated in cationic lipid nanoparticles as describedin Example 2A and delivered to mice as a single bolus, intravenousinjection.

Briefly, male CD-1 mice of approximately 6-8 weeks of age at thebeginning of each experiment were used. Samples of encapsulated HC-αCCL2mRNA and LC-αCCL2 mRNA (1:1 wt:wt) were introduced by a single bolustail-vein injection of an equivalent total dose of 30 micrograms. Micewere sacrificed and perfused with saline at the designated time points.

The liver and spleen of each mouse was harvested, apportioned into threeparts, and stored in either 10% neutral buffered formalin or snap-frozenand stored at −80° C. for analysis.

All animals were euthanized by CO₂ asphyxiation at given time pointspost dose administration followed by thoracotomy and terminal cardiacblood collection. Whole blood (maximal obtainable volume) was collectedvia cardiac puncture on euthanized animals into serum separator tubes,allowed to clot at room temperature for at least 30 minutes, centrifugedat 22° C.±5° C. at 9300 g for 10 minutes, and the serum was extracted.For interim blood collections, approximately 40-50 μL of whole blood wascollected via facial vein puncture or tail snip. Samples collected fromnon-treatment animals were used as baseline levels for comparison tostudy animals.

For ELISA analysis of αCCL2 antibody production, F96 MaxiSorpNunc-Immuno Plate were coated with 100 ml of 1 mg/ml of MCP-1recombinant rabbit purified monoclonal antibody in carbonate buffer, pH9.6 and incubated 1 hr at 37° C. After washing 3× with wash buffer(1×PBS, 0.05% Tween 20), the wells were blocked with 320 ml blockingbuffer (1×PBS, 0.05% Tween 20, 2% BSA) for 1 hr at 37° C. Approximately100 ng/ml MCP-1 human or mouse recombinant protein was added to eachwell and incubated for 1 hr at 37° C. After washing 3× with wash buffer,serial dilutions of the samples (1:5 to 1:200) were added and incubatedfor 1 hr at 37° C. After washing 3× with wash buffer, goat anti-mouseIgG Fc HRP conjugated secondary antibody was used at 1:40,000 dilutionand incubated at 37° C. for 1 hr. After washing 3× with wash buffer TMBEIA substrate reagent was prepared according to manufacturesinstructions. After 15 min incubation at 37° C., the reaction wasstopped by adding 2N H₂SO₄ and the plate read at 450 nm.

Serum levels of treated mice were monitored at select time pointspost-administration (6 hr, 24 hr, 48 hr, 72 hr). The levels of fullyformed α-human CCL2 antibody present in mouse serum were quantifiedusing ELISA-based methods (see FIG. 4). A significant increase in thedesired, exogenous α-CCL2 mRNA derived antibody can be observed withinsix hours post-administration with a peak after 24 hours.

Example 6. In Vivo α-VEGF Antibody Production

In this example, production of fully processed α-VEGF antibody wasaccomplished in vivo via delivery of exogenous messenger RNA.

The sequences for HC-αVEGF and LC-αVEGF are as shown below, and 5′ and3′ untranslated regions present in each mRNA product are represented asX and Y, respectively, and defined below:

Heavy chain anti-VEGF (HC-αVEGF) mRNA: X ₁AUGGCAACUGGAUCAAGAACCUCCCUCCUGCUCGCAUUCGGCCUGCUCUGUCUCCCAUGGCUCCAAGAAGGAAGCGCGUUCCCCACUAUCCCCCUCUCGGAGGUUCAGCUGGUCGAAAGCGGGGGCGGCCUCGUCCAGCCAGGUGGAUCCCUCCGCCUGAGCUGCGCCGCGUCCGGAUACACUUUCACCAACUACGGCAUGAACUGGGUCCGCCAGGCGCCGGGAAAGGGACUGGAAUGGGUCGGCUGGAUCAAUACCUACACUGGAGAGCCUACCUACGCCGCUGACUUUAAGAGGCGGUUCACUUUCUCACUGGAUACUUCCAAGUCAACCGCUUACCUUCAGAUGAAUUCCCUGCGCGCCGAGGAUACCGCAGUGUAUUACUGCGCCAAAUACCCGCAUUACUACGGCUCCAGCCACUGGUACUUUGACGUGUGGGGUCAAGGAACCCUGGUGACUGUGUCGUCCGCUUCCACCAAGGGACCAAGCGUGUUUCCACUCGCCCCGAGCUCAAAAUCGACGUCGGGAGGUACUGCCGCACUGGGGUGCUUGGUCAAGGACUACUUUCCAGAGCCGGUGACUGUUUCCUGGAACAGCGGAGCGCUCACCUCGGGCGUGCACACCUUCCCUGCGGUGUUGCAGUCAUCUGGACUGUACUCGCUGUCCAGCGUGGUCACGGUCCCGAGCUCGUCGCUCGGGACCCAAACCUACAUUUGCAAUGUCAACCACAAGCCAUCGAACACCAAAGUCGACAAGAAGGUGGAACCGAAGUCGUGCGACAAGACUCAUACGUGCCCACCGUGUCCGGCUCCGGAACUGUUGGGGGGCCCCUCCGUGUUCCUUUUCCCGCCAAAGCCUAAGGACACUCUCAUGAUCUCACGGACGCCAGAAGUGACCUGUGUGGUCGUGGAUGUGUCACAUGAGGAUCCGGAAGUCAAAUUCAACUGGUAUGUGGACGGGGUGGAAGUGCAUAAUGCCAAAACCAAACCUCGCGAGGAGCAGUACAACUCAACCUACCGGGUGGUGUCCGUGCUGACUGUGCUGCACCAGGACUGGCUGAAUGGAAAGGAGUACAAAUGCAAGGUCAGCAACAAGGCCCUUCCCGCCCCAAUCGAAAAGACGAUCUCGAAGGCCAAAGGUCAGCCGCGAGAGCCUCAAGUGUACACUCUGCCGCCGUCAAGAGAAGAAAUGACUAAGAACCAAGUUUCCCUCACUUGCCUGGUGAAGGGCUUCUACCCCAGCGACAUCGCAGUGGAAUGGGAGAGCAACGGACAGCCGGAAAACAACUAUAAGACCACCCCUCCUGUGUUGGACUCGGAUGGUUCCUUCUUCCUUUACAGCAAGCUGACCGUGGAUAAAUCGCGGUGGCAGCAAGGAAAUGUGUUUUCAUGCUCAGUCAUGCACGAGGCGCUGCACAAUCACUACACUCAGAAGUCCCUGUCGCUGUCGCCAGGAAAAUAA Y ₁Light chain anti-VEGF (LC-αVEGF) mRNA: X ₁AUGGCCACUGGAUCAAGAACCUCACUGCUGCUCGCUUUUGGACUGCUUUGCCUGCCCUGGUUGCAAGAAGGAUCGGCUUUCCCGACCAUCCCACUCUCCGACAUUCAAAUGACGCAGUCCCCAUCGAGCCUCUCAGCAUCAGUGGGGGAUCGCGUGACUAUCACUUGCUCGGCGAGCCAGGAUAUCAGCAAUUACCUGAACUGGUAUCAGCAAAAGCCUGGAAAGGCACCGAAGGUGCUGAUCUACUUCACCUCAAGCCUCCAUUCGGGUGUCCCGUCCCGCUUCAGCGGCUCCGGCUCAGGCACUGACUUCACCCUGACUAUCUCCUCGCUGCAACCGGAAGAUUUCGCCACUUACUACUGUCAGCAGUACUCCACCGUGCCUUGGACGUUCGGACAGGGAACCAAAGUUGAGAUUAAGCGGACGGUCGCGCCCCCCUCCGUGUUUAUCUUUCCGCCUUCGGACGAGCAGCUGAAGUCGGGAACCGCCUCUGUCGUGUGCCUCCUGAACAACUUCUACCCGCGGGAAGCCAAGGUGCAGUGGAAAGUGGAUAACGCGCUUCAGAGCGGCAAUUCGCAAGAGUCCGUGACCGAAGAGGACUCGAAGGACUCAACCUACUCCCUCAGCUCAACCCUCACUUUGUCGAAGGCCGACUACGAGAAGCACAAAGUCUACGCAUGCGAAGUCACCCACCAGGGUCUGUCGAGCCCAGUGACUAAAUCCUUCAAUAGGGGGGAAUGUUAA Y ₁ 5′ and 3′ UTR Sequences:X₁ (5′ UTR Sequence) =GGACAGAUCGCCUGGAGACGCCAUCCACGCUGUUUUGACCUCCAUAGAAGACACCGGGACCGAUCCAGCCUCCGCGGCCGGGAACGGUGCAUUGGAACGCGGAUUCCCCGUGCCAAGAGUGACUCACCGUCCUUGACACG Y₁ (3′ UTR Sequence) =CGGGUGGCAUCCCUGUGACCCCUCCCCAGUGCCUCUCCUGGCCCUGGAAGUUGCCACUCCAGUGCCCACCAGCCUUGUCCUAAUAAAAUUAAGUUGCAUCAA GCU

α-VEGF heavy chain and light chain mRNA constructs (HC-α-VEGF:LC-α-VEGFmRNA, 1:1 (wt:wt)) were encapsulated in cationic lipid nanoparticles asdescribed below:

In these experiments, aliquots of 50 mg/mL ethanolic solutions ofcKK-E12, DOPE, cholesterol and DMG-PEG2K were mixed and diluted withethanol to 3 mL final volume. Separately, an aqueous buffered solution(10 mM citrate/150 mM NaCl, pH 4.5) of HC-αVEGF mRNA and LC-αVEGF mRNA(1:1 wt:wt) mRNA was prepared by addition of 500 microgram of eachconstruct from a 1 mg/mL stock. The lipid solution was injected rapidlyinto the aqueous mRNA solution and shaken to yield a final suspension in20% ethanol. The resulting nanoparticle suspension was filtered,diafiltrated with 1×PBS (pH 7.4), concentrated and stored at 2-8° C.Final concentration=0.20 mg/mL αVEGF mRNA (encapsulated). Z_(ave)=81.0nm (PDI=0.16).

HC-α-VEGF and LC-α-VEGF mRNA loaded lipid nanoparticles were deliveredto wild type mice either by a single intravenous tail vein injection orsubcutaneous injection at a dosage of 1.0 mg/kg and the production ofanti-VEGF antibody was monitored over time in serum via ELISA.

Briefly, male CD-1 mice of approximately 6-8 weeks of age at thebeginning of each experiment were used. Samples of encapsulatedHC-ca-VEGF mRNA and LC-α-VEGF mRNA (1:1 wt:wt) were introduced by asingle bolus tail-vein injection of an equivalent total dose of 1.0mg/kg (˜30 micrograms). Mice were sacrificed and perfused with saline atthe designated time points (0.50 hour, 3 hours, six hours, 12 hours, 24hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weekspost-administration.

All animals were euthanized by CO₂ asphyxiation at given time pointspost dose administration followed by thoracotomy and terminal cardiacblood collection. Whole blood (maximal obtainable volume) was collectedvia cardiac puncture on euthanized animals into serum separator tubes,allowed to clot at room temperature for at least 30 minutes, centrifugedat 22° C.±5° C. at 9300 g for 10 minutes, and the serum was extracted.For interim blood collections, approximately 40-50 μL of whole blood wascollected via facial vein puncture or tail snip. Samples collected fromnon-treatment animals were used as baseline levels for comparison tostudy animals

For ELISA analysis of α-VEGF antibody production, F96 MaxiSorpNunc-Immuno Plate were coated with 100 microliters of 0.50microgram/ml/well of recombinant human VEGF protein (Invitrogen #PHC9391) in coating buffer (50 mM NaHCO₃, pH9.6). After washing 3× withwash buffer, wells were blocked using a blocking buffer (1×DPBS, 2% BSA,0.05% Tween-20) for one hour at 37° C. Upon further washing as describedabove, mouse serum collected from injected mice were added to each welland rabbit anti-human IgG Fc HRP (Pierce # PA-28587) conjugatedsecondary antibody was used at 1:10,000 dilution and incubated at 37° C.for 1 hr. After washing 3× with wash buffer TM B EIA substrate reagentwas prepared according to manufactures instructions. After 10 minincubation at 37° C., the reaction was stopped by adding 2N H₂SO₄ andthe plate read at 450 nm. Serum levels of treated mice were monitored atselect time points post-administration (e.g., 0.5 hr, 3 hr, 6 hr, 12 hr,24 hr, 48 hr, 72 hr, 96 hr, 8 days and 15 days). FIG. 5 depictsexemplary results illustrating α-VEGF antibody detected in serum of wildtype mice after single dose of HC-α-VEGF mRNA and LC-α-VEGF mRNA loadednanoparticles. A significant increase in the desired, exogenous α-VEGFmRNA derived antibody can be observed within six hourspost-administration with a peak after 24 hours and continued out to 2weeks after a single dose of α-VEGF mRNA. FIG. 6 depicts the sameexemplary results as FIG. 5, but plotted by specific mouse number. FIG.7 shows a comparison of the levels of α-VEGF antibody present in theserum of mice injected either intravenously or subcutaneously after 24hours.

This example provides further confirmation that mRNA based therapy canbe used for effective in vivo antibody production.

EQUIVALENTS AND SCOPE

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments of the invention described herein. The scope of the presentinvention is not intended to be limited to the above Description, butrather is as set forth in the following claims:

1-51. (canceled)
 52. A method of delivering an antibody in vivo, themethod comprising: administering to a subject in need thereof a firstmRNA polynucleotide encoding an antibody heavy chain, and a second mRNApolynucleotide encoding an antibody light chain, wherein the first mRNApolynucleotide encoding the antibody heavy chain and the second mRNApolynucleotide encoding the antibody light chain are present at a molarratio of greater than 1, respectively, wherein the first mRNApolynucleotide and the second mRNA polynucleotide are separate, andwherein the antibody is expressed systemically in the subject.
 53. Themethod of claim 52, wherein the first mRNA polynucleotide and the secondmRNA polynucleotide are encapsulated within a same liposome.
 54. Themethod of claim 52, wherein the first mRNA polynucleotide and the secondmRNA polynucleotide are encapsulated in separate liposomes,respectively.
 55. The method of claim 53, wherein the liposomes compriseone or more of cationic lipid, non-cationic lipid, and PEG-modifiedlipid.
 56. The method of claim 54, wherein the liposomes comprise one ormore of cationic lipid, non-cationic lipid, and PEG-modified lipid. 57.The method of claim 52, wherein the first mRNA polynucleotide or thesecond mRNA polynucleotide comprises a modified nucleotide, a capstructure, a poly A tail, a 5′ and/or 3′ untranslated region.
 58. Themethod of claim 52, wherein the first mRNA polynucleotide and the secondmRNA polynucleotide are administered intravenously.
 59. The method ofclaim 52, wherein the first mRNA polynucleotide and the second mRNApolynucleotide are administered intraperitoneally.
 60. The method ofclaim 52, wherein the systemic expression of the antibody is detectableat least about 6 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72hours, 96 hours or 120 hours post-administration.
 61. The method ofclaim 52, wherein the antibody is selected from the group consisting ofanti-CCL2, anti-lysyl oxidase-like-2 (LOXL2), anti-Flt-1, anti-TNF-α,anti-Interleukin-2Rα receptor (CD25), anti-TGF_(β), anti-B-cellactivating factor, anti-alpha-4 integrin, anti-BAGE, anti-β-catenin/m,anti-Bcr-abl, anti-C5, anti-CA125, anti-CAMEL, anti-CAP-1, anti-CASP-8,anti-CD4, anti-CD19, anti-CD20, anti-CD22, anti-CD25, anti-CDC27/m,anti-CD 30, anti-CD33, anti-CD52, anti-CD56, anti-CD80, anti-CDK4/m,anti-CEA, anti-CT, anti-CTL4, anti-Cyp-B, anti-DAM, anti-EGFR,anti-ErbB3, anti-ELF2M, anti-EMMPRIN, anti-EpCam, anti-ETV6-AML1,anti-HER2, anti-G250, anti-GAGE, anti-GnT-V, anti-Gp100, anti-HAGE,anti-HER-2/neu, anti-HLA-A*0201-R170I, anti-IGF-1R, anti-IL-2R,anti-IL-5, anti-MC1R, anti-myosin/m, anti-MUC1, anti-MUM-1, -2, -3,anti-proteinase-3, anti-p190 minor bcr-abl, anti-Pml/RARα, anti-PRAMS,anti-PSA, anti-PSM, anti-PSMA, anti-RAGE, anti-RANKL, anti-RU1 or RU2,anti-SAGE, anti-SART-1 or anti-SART-3, anti-survivin, anti-TEL/AML1,anti-TPI/m, anti-TRP-1, anti-TRP-2, anti-TRP-2/INT2, anti-VEGF, andanti-VEGF receptor.
 62. A method of producing an antibody, the methodcomprising: administering to a cell a first mRNA polynucleotide encodingan antibody heavy chain and a second mRNA polynucleotide encoding anantibody light chain or a fragment thereof, wherein the first mRNApolynucleotide encoding the antibody heavy chain and the second mRNApolynucleotide encoding the antibody light chain are present at a molarratio of greater than 1, respectively, wherein the first mRNApolynucleotide and the second mRNA polynucleotide are separate, andwherein the antibody is produced by the cell.
 63. The method of claim62, wherein the antibody is secreted by the cell.
 64. The method ofclaim 62, wherein the first mRNA polynucleotide and the second mRNApolynucleotide are encapsulated in one or more liposomes.
 65. Acomposition comprising a first mRNA polynucleotide encoding an antibodyheavy chain or a fragment thereof, and a second mRNA polynucleotideencoding an antibody light chain or a fragment thereof, wherein thefirst mRNA polynucleotide encoding the antibody heavy chain and thesecond mRNA polynucleotide encoding the antibody light chain are presentat a molar ratio of greater than 1, respectively, wherein the first mRNApolynucleotide and the second mRNA polynucleotide are encapsulated inone or more liposomes.
 66. The composition of claim 65, wherein thefirst mRNA polynucleotide and the second mRNA polynucleotide areencapsulated within a same liposome.
 67. The composition of claim 65,wherein the first mRNA polynucleotide and the second mRNA polynucleotideare encapsulated in separate liposomes, respectively.
 68. Thecomposition of claim 66, wherein the one or more liposomes comprise oneor more of cationic lipid, non-cationic lipid, and PEG-modified lipid.69. The composition of claim 67, wherein the one or more liposomescomprise one or more of cationic lipid, non-cationic lipid, andPEG-modified lipid.
 70. The composition of claim 66, wherein the one ormore liposomes have a size no greater than approximately 250 nm, 225 nm,200 nm, 175 nm, 150 nm, 125 nm, 100 nm, 75 nm, or 50 nm.